Evidence-Based Practice Group Answers to Clinical Questions

“Treating Mesothelioma: Reviewing Multiple Treatment Modalities” or “Multiple Treatment Modalities Offered at Certain Clinic to Treat Mesothelioma”

A Rapid Systematic Review

By

WorkSafeBC Evidence-Based Practice Group

Dr. Craig Martin Manager, Clinical Services Chair, Evidence-Based Practice Group

January 2016

Clinical Services – Worker and Employer Services

Treating Mesothelioma: Reviewing Multiple Treatment Modalities i

About this report

“Treating Mesothelioma: Reviewing Multiple Treatment Modalities” or “Multiple Treatment Modalities Offered at Certain Clinic to Treat Mesothelioma”

Published: January 2016

About the Evidence-Based Practice Group The Evidence-Based Practice Group was established to address the many medical and policy issues that WorkSafeBC officers deal with on a regular basis. Members apply established techniques of critical appraisal and evidence-based review of topics solicited from both WorkSafeBC staff and other interested parties such as surgeons, medical specialists, and rehabilitation providers.

Suggested Citation WorkSafeBC Evidence-Based Practice Group, Martin CW. Treating Mesothelioma: Reviewing Multiple Treatment Modalities” or “Multiple Treatment Modalities Offered at Certain Clinic to Treat Mesothelioma. Richmond, BC: WorksafeBC Evidence-Based Practice Group; January 2016.

Contact Information Evidence-Based Practice Group WorkSafeBC PO Box 5350 Stn Terminal Vancouver BC V6B 5L5

Email  [email protected] Phone  604 279-7417 Toll-free  1 888 967-5377 ext 7417

View other systematic reviews by the EBPG online at: http://worksafebc.com/evidence

WorkSafeBC Evidence-Based Practice Group January 2016 www.worksafebc.com/evidence Treating Mesothelioma: Reviewing Multiple Treatment Modalities 1

Objective

To determine whether there is evidence on the efficacy or effectiveness and safety of the treatment modalities for mesothelioma offered at some centres in the United States. These treatments include genetically targeted fractionated chemotherapy, autologous adoptive immunotherapy, natural killer cell vaccine, intravenous nutrition therapy, oxidative therapy and biodetoxification.

Methods

• A systematic literature search was conducted on September 23, 2013.

• The search was done on commercial medical literature databases, including Cochrane Database of Systematic Reviews®, ACP Journal Club®, Database of Abstracts of Reviews of Effects®, Cochrane Central Register of Controlled Trials®, Health Technology Assessment®, NHS Economic Evaluation Database®, BIOSIS Previews®, Embase®, International Pharmaceutical Abstracts®, MEDLINE®, MEDLINE In- Process & Other Non-Indexed Citations®, MEDLINE Daily Update® and OLDMEDLINE®, that are available through OvidSP® platform.

• The search was done from the inception date of each database to September 23, 2013.

• No limitations, such as on publication language or date of publication, were implemented in these searches.

• In order answer to this review’s stated objective, the searches were done in several stages by employing the following keywords combintations or author's name(s):

o (envita medical centers of America) or (envita medical centers) or envita. No published study done at this clinic or by authors affiliated with this clinic was found.

o prato.au. OR (korn or korn b).au.

. According to the information available on the Envita website (http://www.envita.com/), Dino D. Prato, ND (naturopath), is the founder and CEO of the Envita Clinic.

. Based on claims of success in treating numerous types of diseases (from on information on the clinic’s website), we expected to see a number of publications of studies/study

WorkSafeBC Evidence-Based Practice Group January 2016 www.worksafebc.com/evidence Treating Mesothelioma: Reviewing Multiple Treatment Modalities 2

results in formal, peer-reviewed medical journals that may be attributed to the Envita clinic or by the founder/clinicians affilitated with the clinic.

. By employing the last name of the clinic's founder (Prato) as well as the last name of other physicians at the clinic, 286 (ref. 1-286) published studies were identified through this search.

. However, upon examination of the titles and abstracts of these 286 articles (ref. 1-286) none of these studies were relevant to the objective of this systematic review.

o (genetically targeted fractionated chemotherapy) OR (genetically matched chemotherapy). No published study on the topic of genetically targeted fractionated chemoteraphy was identified.

o (autologous adoptive immunotherapy).

. Twenty (ref. 287-297) published studies were identified by employing this keyword combination.

. Upon examination of the titles and abstracts of these 20 studies (ref. 287-297), none of these studies were relevant to answering the objective of this systematic review.

o (natural killer cell vaccine).

. Three (ref. 298-300) published studies were identified through this search. However, upon examination of the titles and abstracts of these papers, none were relevant to answering the objective of this systematic review.

o (intravenous nutrition therapy).

. Nine (ref. 301-309) published studies were identified through this search. However, none of these nine articles (ref. 301-309) were relevant in answering our objective.

o (((oxidative therapy) OR biodetoxification) AND mesothelioma). No published study was identified through this search.

WorkSafeBC Evidence-Based Practice Group January 2016 www.worksafebc.com/evidence Treating Mesothelioma: Reviewing Multiple Treatment Modalities 3

Results

• At present, there are no published studies identified regarding the efficacy or effectiveness of the treatments (genetically targeted fractionated chemotherapy, autologous adoptive immunotherapy, natural killer cell vaccine, intravenous nutrition therapy, oxidative therapy and biodetoxification) proposed by the Envita clinic to treat patients diagnosed with mesothelioma. As such, it is not possible to assess the efficacy/effectiveness, or safety, of these treatment modalities.

• Through daily literature surveillance, which includes literature on the topic of mesothelioma, the Evidence-Based Practice Group possess two recent, high quality systematic reviews (level of evidence 1. Appendix 1) investigating the effectiveness of different chemotherapy and immunotherapy regimens for patient with mesothelioma (ref. 310) and an evidence-based guideline for the diagnosis and treatment of malignant pleural mesothelioma (ref. 311-313). These two high quality level 1 evidence are as follows:

1. Berghmans et al. (ref. 310) conducted a meta-analysis investigating the effectiveness of various chemo- and immunotherapies in treating patients diagnosed with malignant mesothelioma.

2. The Asbestos Diseases Research Institute of Australia (ADRI) (ref. 311-313) developed a high quality, evidence-based, comprehensive guideline on the management of malignant pleural mesothelioma.

• With regard to the role of immunotherapy in treating mesothelioma patients, both the Berghmans and ADRI studies stated that there was no evidence supporting the effectiveness of immunotherapy and the modality should only be used in experimental studies.

• The comprehensive and evidence-based ADRI guidelines are the most up to date guidelines available. They emphasize the importance of having a multidisciplinary team involved in the management of patients diagnosed with mesothelioma. Below are some (and perhaps the most) important aspects on the management of patients with mesothelioma:

o A multidisciplinary team approach will ensure consistency in patient management through the development of a multidisciplinary care plan that will guide patient treatment throughout their illness and provide support for their caregivers.

WorkSafeBC Evidence-Based Practice Group January 2016 www.worksafebc.com/evidence Treating Mesothelioma: Reviewing Multiple Treatment Modalities 4

Allied health professionals are important members of the multidisciplinary team and contribute to symptom management and improved quality of life in patients with malignant mesothelioma. Current practice tells us that allied health professionals are integral members of multidisciplinary team and may come from the following disciplines: nutrition and dietetics, occupational therapy, social work, clinical psychology, physiotherapy and pastoral care. Patients can be referred to these professionals at any time during their disease course and treatment trajectory. However, at present, no studies have been conducted on the impact of allied health professional input on the outcomes for patients with malignant pleural mesothelioma.

o Combination chemotherapy (pemetrexed and cisplatin or carboplatin) rather than single drug treatment should be used as first-line systemic treatment for malignant pleural mesothelioma.

o Thoracoscopic pleurodesis is an effective treatment option to control recurrent malignant pleural effusions in mesothelioma. If the thoracoscopic pleurodesis is not appropriate or fails, palliative pleurectomy/decortication should be considered for symptom control.

o Only patients with favourable prognostic features, and favourable histology and staging, should be referred for consideration of radical treatment involving extensive cytoreductive surgery.

o Radical surgical approaches should only be done at institutions with significant surgical experience and a high volume of cases. Extensive cytoreductive surgery should only be used as one element of a multimodality treatment plan.

o Mesothelioma is sensitive to moderately high radiation doses and radiotherapy is advocated for palliation of symptomatic tumour masses arising from the pleural cavity or metastases in other locations.

WorkSafeBC Evidence-Based Practice Group January 2016 www.worksafebc.com/evidence Treating Mesothelioma: Reviewing Multiple Treatment Modalities 5

Summary

• At present, there is no published evidence to support the efficacy or effectiveness of genetically targeted fractionated chemotherapy, autologous adoptive immunotherapy, natural killer cell vaccine, intravenous nutrition therapy, oxidative therapy and biodetoxification in treating patients diagnosed with mesothelioma. At present, there are no published studies that investigate the potential harm to patients due to the provision of these treatments.

References

1. Abba, M.; Laufs, S.; Aghajany, M.; Korn, B.; Benner, A., and Allgayer, H. Look who's talking: Deregulated signaling in colorectal cancer. Cancer. Genomics and Proteomics. 9 (1) (pp 15-25), 2012. 2. Abdrakhmanov, I.; Lodygin, D.; Geroth, P.; Arakawa, H.; Law, A.; Plachy, J.; Korn, B., and Buerstedde J.-M. A large database of chicken bursal ESTs as a resource for the analysis of vertebrate gene function. Genome. Research. 10 (12) (pp 2062-2069), 2000. 3. Abendroth, D. Buchholz B, Land W, May G, Wiesel M, Farber L, Korn A, Maibucher A. Comparison of efficacy, safety, and tolerability of Neoral vs Sandimmun in de novo renal transplant patients over 24 months' treatment. Transplantation. proceedings. 29(1-2):275-6, 1997 Feb-Mar. 4. Amann P.M.; Schadendorf, D.; Owen R.W.; Korn, B.; Eichmuller S.B., and Bazhin A.V. Corrigendum to Letter to the Editor: Retinal and retinol are potential regulators of gene expression in the keratinocyte cell line HaCaT. Experimental. Dermatology. 20 (4) (pp 375), 2011. Date of Publication: April 2011. 5. Amann P.M.; Schadendorf, D.; Owen R.W.; Korn, B.; Eichmuller S.B., and Bazhin A.V. Retinal and retinol are potential regulators of gene expression in the keratinocyte cell line HaCaT. Experimental. Dermatology. 20 (4) (pp 373-375), 2011. Date of Publication: April 2011. 6. Ammerpohl, O.; Bens, S.; Appari, M.; Werner, R.; Korn, B.; Drop, S. L.; Verheijen, F.; van der Zwan, Y.; Bunch, T.; Hughes, I.; Cools, M.; Riepe, F. G.; Hiort, O.; Siebert, R., and Holterhus, P. M. Androgen receptor function links human sexual dimorphism to DNA methylation. PLoS. ONE [Electronic Resource]. 8(9):e73288, 2013. 7. Ammerpohl, O.; Haake, A.; Pellissery, S.; Giefing, M.; Richter, J.; Balint, B.; Kulis, M.; Le, J.; Bibikova, M.; Drexler H.G.; Seifert, M.; Shaknovic, R.; Korn, B.; Kuppers, R.; Martin-Subero J.I., and Siebert, R. Array-based DNA methylation analysis in classical Hodgkin lymphoma reveals new insights into the mechanisms underlying silencing of B cell-specific genes. Leukemia. 26 (1) (pp 185-188), 2012. Date of Publication: January 2012.

WorkSafeBC Evidence-Based Practice Group January 2016 www.worksafebc.com/evidence Treating Mesothelioma: Reviewing Multiple Treatment Modalities 6

8. Appel, S. Paradis K, Korn A, Jean C, Winkler M, Kliem V, Hauser I, Renders L, Budde K, Neumayer HH. Safety, tolerability, and pharmacokinetics of the new immunosuppressant SDZ RAD in stable renal transplant recipients [abstract no:359]. 16th. Annual Meeting. American Society of Transplant Physicians (ASTP); . 1997 May 10-14; Chicago (ILL) 174p. 1997. 9. Bachner, D.; Sedlacek, Z.; Korn, B.; Hameister, H., and Poustka, A. Expression patterns of two human genes coding for different rab GDP-dissociation inhibitors (GDIs), extremely conserved proteins involved in cellular transport. Human. Molecular Genetics. 4 (4) (pp 701-708), 1995. Date of Publication: April 1995. 10. Badian, M. Korn A, Lehr KH, Malerczyk V, Waldhausl W. Absolute bioavailability of glimepiride (Amaryl) after oral administration. Drug. metabolism and drug interactions. 11(4):331-9, 1994. 11. Badian, M. Korn A, Lehr KH, Malerczyk V, Waldhausl W. Pharmacokinetics and pharmacodynamics of the hydroxymetabolite of glimepiride (Amaryl) after intravenous administration. Drug. metabolism and drug interactions. 13(1):69-85, 1996. 12. Balabanova, S. And Korn, B. Effect of nicotine on the secretion of immunoreactive parathyroid hormone by the brain. Acta. Endocrinologica Supplementum. 114(283):90, 1987. 13. Balbarini, A.; Felice, F.; Barsotti M.C.; Pucci, L.; Lucchesi, D.; Penno, G.; Prato S.D., and Di Stefano, R. Oxidative stress in response to high glucose levels in endothelial cells and in endothelial progenitor cells. Evidence for differential responses. Journal. of the American College of Cardiology. Conference: American College of Cardiology's 59th Annual Scientific Session and i2 Summit: Innovation in Intervention Atlanta, GA United States. 14. Bartholomae, C. C.; Arens, A.; Balaggan, K. S.; Yanez-Munoz, R. J.; Montini, E.; Howe, S. J.; Paruzynski, A.; Korn, B.; Appelt, J. U.; Macneil, A.; Cesana, D.; Abel, U.; Glimm, H.; Naldini, L.; Ali, R. R.; Thrasher, A. J.; von Kalle, C., and Schmidt, M. Lentiviral vector integration profiles differ in rodent postmitotic tissues. Molecular. Therapy: the Journal of the American Society of Gene Therapy. 19(4):703-10, 2011 Apr. 15. Baumrind, S. Poulton D, Korn EL, Boyd R, et al. A randomized clinical trial of orthodontic therapy . Journal. of Dental Research. 70(Spec Iss):1991. 16. Bazzino, O. Barrero C, Garre L, Sosa A, Aylward P, Slany J, Beaudry P, Bedard J, DeLarochelliere R, Nguyen M, Bogaty P, Boudreault JR, Diodati JG, Dupuis J, Fitchett D, Fung A, Gervais P, Gossard D, Grandmont D, Huynh T, Kouz S, Langer A, Laramee P, Lemay M, Maillette S, Maranda C, Nasmith J, Pesant Y, Phanuef D, Proulx G, Ruel M, Thompson C, Corbalan R, Botero R, Husted S, Heikkila J, Charbonnier B, Moguel R, Commerford P, Landless P, Weich D, Maritz F, Marx J, Fernandes F, Lidon R, Sanz G, Bosch X, Moccetti T, Ali N, Anderson HV, Bajwa T, Borzak S, Boyek T, Brewer D, Cambier P, Chivukula S, Corder C, Ezekowitz M, Feldman R, Glickman L, Jang IK, Klein M, Korn D, Krauss S, Kwan T, Mann JT, Marshall J, Martin J, Monrad ES, Mueller H, Penny W, Schmedtje J, Strony J, Armstrong P, DeCani J, Hirsh J, Pepine C, Ryan TJ, Theroux P, Catella-Lawson F, Roy L, Willerson JT, Yusuf S, Zhao X, Sax FL, Harris KH, Pelletier G, Davies R, Flather M, Gosselin G, Herrmann H, Kells C, Knudtson M, Thadani U, Snapinn SM, Ghannam A, Haggert B, Watson A, Lis J, et al. Inhibition of

WorkSafeBC Evidence-Based Practice Group January 2016 www.worksafebc.com/evidence Treating Mesothelioma: Reviewing Multiple Treatment Modalities 7

the platelet glycoprotein IIb/IIIa receptor with tirofiban in unstable angina and non- Q-wave myocardial infarction. New. England Journal of Medicine. 338(21):1488- 1497, 1998. 17. Beeh, K. M. Korn S, Beier J, Jadayel D, Henley M, Tylek J, et al. QVA149 once daily improves exercise tolerance and lung function in patients with moderate to severe COPD: the BRIGHT study . Thorax. 67(Suppl 2):A147 [P191], 2012. 18. Beissbarth, T.; Borisevich, I.; Horlein, A.; Kenzelmann, M.; Hergenhahn, M.; Klewe- Nebenius, A.; Klaren, R.; Korn, B.; Schmid, W.; Vingron, M., and Schutz, G. Analysis of CREM-dependent gene expression during mouse spermatogenesis. Molecular. and Cellular Endocrinology. 212 (1-2) (pp 29-39), 2003. Date of Publication: 30 Dec 2003. 19. Bello V.D.; Talini, E.; Dell'Omo, G.; Giannini, C.; Delle Donne M.G.; Canale M.L.; Nardi, C.; Palagi, C.; Dini F.L.; Penno, G.; Prato S.D.; Marzilli, M., and Pedrinelli, R. Early left ventricular mechanics abnormalities in prehypertension: A two-dimensional strain echocardiography study. American. Journal of Hypertension. 23 (4) (pp 405- 412), 2010. Date of Publication: April 2010. 20. Berg, G. D. Silverstein S, Thomas E, Korn AM. Cost and utilization avoidance with mail prompts: a randomized controlled trial. The. American journal of managed care. 14(11):748-54, 2008 Nov. 21. Bianchi, C.; Miccoli, R.; Trombetta, M.; Giorgino, F.; Frontoni, S.; Faloia, E.; Marchesini, G.; Dolci M.A.; Cavalot, F.; Cavallo, G.; Leonetti, F.; Bonadonna R.C., and Prato S.D. Elevated 1-hour postload plasma glucose levels identify subjects with normal glucose tolerance but impaired beta-cell function, insulin resistance, and worse cardiovascular risk profile: The GENFIEV study. Journal. of Clinical Endocrinology and Metabolism. 98 (5) (pp 2100-2105), 2013. Date of Publication: May 2013. 22. Blochl-Daum, B. Korn A, Wolzt M, Schmidt E, Eichler H-G. In vivo studies on alpha- adrenergic receptor subtypes in human veins. Naunyn-Schmiedebergs. Archives of Pharmacology. 344(3):302-307, 1991. 23. Boer, J. M.; Huber, W. K.; Sultmann, H.; Wilmer, F.; von Heydebreck, A.; Haas, S.; Korn, B.; Gunawan, B.; Vente, A.; Fuzesi, L.; Vingron, M., and Poustka, A. Identification and classification of differentially expressed genes in renal cell carcinoma by expression profiling on a global human 31,500-element cDNA array. Genome. Research. 11(11):1861-70, 2001 Nov. 24. Boer, J. M. ; Gunawan, B. ; Wilmer, F. ; Korn, B. ; Vingron, M. ; Fuezesi, L. , and Poustka, A. . Gene expression profiling of clear cell renal cell carcinomas using complex hybridization. Pathology. Research & Practice. 196(6):392, 2000. 25. Boggi, U.; Vistoli, F.; Chiaro M.D.; Signori, S.; Pietrabissa, A.; Costa, A.; Bartolo T.V.; Catalano, G.; Marchetti, P.; Prato S.D.; Rizzo, G.; Jovine, E.; Pinna A.D.; Filipponi, F., and Mosca, F. A simplified technique for the en bloc procurement of abdominal organs that is suitable for pancreas and small-bowel transplantation. Surgery. 135 (6) (pp 629-641), 2004. Date of Publication: June 2004. 26. Boggi, U.; Vistoli, F.; Del Chiaro, M.; Signori, S.; Croce, C.; Pietrabissa, A.; Berchiolli, R.; Marchetti, P.; Prato, S. D., and Mosca, F. Pancreas preservation with University of Wisconsin and Celsior solutions: a single-center, prospective, randomized pilot study. Transplantation. 77(8):1186-90, 2004 Apr 27.

WorkSafeBC Evidence-Based Practice Group January 2016 www.worksafebc.com/evidence Treating Mesothelioma: Reviewing Multiple Treatment Modalities 8

27. Bohler, T. Waiser J, Budde K, Lichter S, Jauho A, Fritsche L, Korn A, Neumayer HH. The in vivo effect of rapamycin derivative SDZ RAD on lymphocyte proliferation. Transplantation. proceedings. 30(5):2195-7, 1998 Aug. 28. Bola, O.; Zippe, P.; Wolte, M.; Korn, B., and Reifenberge, G. Characterization of differential microRNA expression in medulloblastoma. Acta. Neuropathologica. Conference: 54. Annual Meeting of the German Society of Neuropathology and Neuroanatomy, DGNN Dusseldorf Germany. 29. Booij, J. Korn P, Linszen DH, van Royen EA. Assessment of endogenous dopamine release by methylphenidate challenge using iodine-123 iodobenzamide single-photon emission tomography. European. journal of nuclear medicine. 24(6):674-7, 1997 Jun. 30. Borenstein, D. G. Korn S. Efficacy of a low-dose regimen of cyclobenzaprine hydrochloride in acute skeletal muscle spasm: results of two placebo-controlled trials. Clinical. therapeutics. 25(4):1056-73, 2003 Apr. 31. Bork, S.; Pfister, S.; Witt, H.; Horn, P.; Korn, B.; Ho A.D., and Wagner, W. DNA methylation pattern changes upon long-term culture and aging of human mesenchymal stromal cells. Aging. cell. 9 (1) (pp 54-63), 2010. Date of Publication: Feb 2010. 32. Bourbeillon, J.; Orchard, S.; Benhar, I.; Borrebaeck, C.; De Daruvar, A.; Dubel, S.; Frank, R.; Gibson, F.; Gloriam, D.; Haslam, N.; Hiltker, T.; Humphrey-Smith, I.; Hust, M.; Juncker, D.; Koegl, M.; Konthur, Z.; Korn, B.; Krobitsch, S.; Muyldermans, S.; Nygren P.-A.; Palcy, S.; Polic, B.; Rodriguez, H.; Sawyer, A.; Schlapshy, M.; Snyder, M.; Stoevesandt, O.; Taussig M.J.; Templin, M.; Uhlen, M.; Van Der Maarel, S.; Wingren, C.; Hermjakob, H., and Sherman, D. Minimum information about a protein affinity reagent (MIAPAR). Nature. Biotechnology. 28 (7) (pp 650-653), 2010. Date of Publication: July 2010. 33. Bratusch-Marrain, P. R. Korn A, Waldhausl WK, et al. Effect of buformin on splanchnic carbohydrate and substrate metabolism in healthy man. Metabolism. Clinical & Experimental. 30(10):946-952, 1981. 34. Brazma, A.; Freeman, T.; Gardiner, K.; Weissman, S.; Werner, T., and Korn, B. Report on the thirteenth international workshop on the identification and functional, evolutionary and expression analysis of transcribed sequences: Comparative and functional genomics workshop. Cytogenetic. and Genome Research. 105 (1) (pp 11- 17), 2004. Date of Publication: 2004. 35. Breidenbach, T. Korn A, Maibucher A, Schlitt HJ, Oldhafer KJ, Kliem V, Brunkhorst R, Schmidt AG, Nashan B. Two years results of a clinical trial with basiliximab (Simulect) in renal transplantation . XVII. World Congress of the Transplantation Society; . 1998 Jul 12-17; Montreal, Canada 1998. 36. Breidenbach, T. Korn A, Maibucher A, Schlitt HJ, Oldhafer KJ, Kliem V, Brunkhorst R, Schmidt AG, Nashan B. Basiliximab (Simulect) reduces acute rejections, CMV infections and duration of hospital stay in renal allograft patients . Transplantation. 65(12):S180, 1998. 37. Breitling L.P.; Yang, R.; Korn, B.; Burwinkel, B., and Brenner, H. Tobacco-smoking- related differential DNA methylation: 27K discovery and replication. American. Journal of Human Genetics. 88 (4) (pp 450-457), 2011. Date of Publication: 08 Apr 2011.

WorkSafeBC Evidence-Based Practice Group January 2016 www.worksafebc.com/evidence Treating Mesothelioma: Reviewing Multiple Treatment Modalities 9

38. Brockmann, C.; Diehl, A.; Rehbein, K.; Strauss, H.; Schmieder, P.; Korn, B.; Kuhne, R., and Oschkinat, H. The oxidized subunit B8 from human complex I adopts a thioredoxin fold. Structure. 12 (9) (pp 1645-1654), 2004. Date of Publication: September 2004. 39. Bruch, H. R. Korn A, Klein H, Markus R, Malmus K, Baumgarten R, Muller R. Treatment of chronic hepatitis B with interferon alpha-2b and interleukin-2. Journal. of hepatology. Vol.17 Suppl 3, pp.S52-5, 1993. 40. Brueck, M. Scheinert D, Maeffert R, Wortmann A, Bremer J, von Korn H, Flachskampf FA, and LJ. Direct coronary stenting versus predilation followed by stent placement. A randomized study with angiographic follow-up. Zeitschrift. Fur Kardiologie. 91(Suppl 1):I/72, 2002. 41. Brueck, M. Scheinert D, Maeffert R, Wortmann A, Bremer J, von Korn H, Flachskampf FA, and LJ. Direct coronary stenting versus predilatation followed by stent placement. The. American journal of cardiology. 90(11):1187-92, 2002 Dec. 42. Bruno R.M.; Ghiadoni, L.; Penno, G.; Taddei, S., and Prato S.D. Might hypovitaminosis D aggravate endothelial dysfunction-Related increases in arterial stiffness seen in patients with hypertension and type 2 diabetes? Reply to Boucher BJ [letter]. Diabetologia. 55 (11) (pp 3142-3143), 2012. Date of Publication: November 2012. 43. Buchholz, B. Korn A. Safety and tolerability of Sandimmun Neoral vs Sandimmun in de novo renal transplant patients after 24 months' treatment. German Neoral Study Group. Transplantation. proceedings. 28(4):2187-8, 1996 Aug. 44. Buerstedde J.-M.; Arakawa, H.; Watahiki, A.; Carninci P.P.; Hayashizaki Y.Y.; Korn, B., and Plachy, J. The DT40 web site: Sampling and connecting the genes of a B cell line. Nucleic. Acids Research. 30 (1) (pp 230-231), 2002. Date of Publication: 01 Jan 2002. 45. Buhlmann, C. ; Zink, D. ; Salowsky, R. ; Haas, S. , and Korn, B. . High throughput experimental verification of predicted tissue and tumor specific splice isoforms. EJC. Supplements. 3(2, Suppl. S):56, OCT 2005. 46. Chamoun, Z. ; Dahmane, N. ; Lopes, C. ; Dufresne-Zacharia, M. C. ; Chettouh, Z. ; Korn, B. ; Poutska, A. M. ; Yaspo, M. L. ; Lehrach, H. ; Sinet, P. M. , and Delabar, J. M. . New transcripts from the Down syndrome chromosomal region. Cytogenetics. & Cell Genetics. 77(SUPPL. 1):32, 1997. 47. Csendes, A.; Silva, A.; Burdiles, P.; Diaz, J. C.; Korn, O., and Maluenda, F. Antibiotic prophylaxis in laparascopic cholecystectomy: a prospective randomised trial. Revista. chilena de cirugia. 47(2):145-7, 1995. 48. Csendes, A. Braghetto I, Burdiles P, Diaz JC, Maluenda F, Korn O. A new physiologic approach for the surgical treatment of patients with Barrett's esophagus: technical considerations and results in 65 patients. Annals. of surgery. 226(2):123-33, 1997 Aug. 49. Csendes, A. Braghetto I, Burdiles P, Diaz JC, Maluenda F, Korn O. Late results of a randomized clinical trial comparing total fundoplication versus calibration of the cardia with posterior gastropexy. The. British journal of surgery. 87(3):289-97, 2000 Mar. 50. Csendes, A. Braghetto I, Burdiles P, Diaz JC, Maluenda F, Korn O. 'Carditis': an objective histological marker for pathologic gastroesophageal reflux disease.

WorkSafeBC Evidence-Based Practice Group January 2016 www.worksafebc.com/evidence Treating Mesothelioma: Reviewing Multiple Treatment Modalities 10

Diseases. of the esophagus : official journal of the International Society for Diseases of the Esophagus / I.S.D.E. 11(2):101-5, 1998 Apr. 51. Csendes Juhasz, A. Diaz JC, Burdiles Pinto P, Maluenda F, Korn Bruzzone O. [Use of external surgical biliary drainages: cysticostomy and cholecystotomy in biliopancreatic patients]. Revista. Chilena de Cirugia. 46(6):587-91, 1994. 52. Csendes Juhasz, A. Diaz JC, Burdiles Pinto P, Maluenda F, Korn Bruzzone O. Antibiotic prophylaxis in laparoscopic cholecystectomy: randomized prospective study. Revista. Chilena De Cirugia. 47(2):145-7, 1995. 53. Cutler, N. R. ; Sramek, J. J. ; Shrotriya, R. ; Alms, D. ; Korn, B. , and Macpherson, A. E. . Extended release (ER) formulation of buspirone in generalized anxiety disorder. Biological. Psychiatry. 35(9):680, 1994. 54. Dahmane, N.; Ghezala G.A.; Gosset, P.; Chamoun, Z.; Dufresne-Zacharia M.-C.; Lopes, C.; Rabatel, N.; Gassanova-Maugenre, S.; Chettouh, Z.; Abramowski, V.; Fayet, E.; Yaspo M.-L.; Korn, B.; Blouin J.-L.; Lehrach, H.; Poutska, A.; Antonarakis S.E.; Sinet P.-M.; Creau, N., and Delabar J.-M. Transcriptional map of the 2.5-Mb CBR-ERG region of chromosome 21 involved in Down syndrome. Genomics. 48 (1) (pp 12-23), 1998. Date of Publication: 15 Feb 1998. 55. Daniele, A.; Ghiadoni, L.; Bruno, R.; Pucci, L.; Lucchesi, D.; Storti, E.; Russo, E.; Bianchi, C.; Taddei, S.; Miccoli, R.; Penno, G., and Prato S.D. Endothelial function is associated with arterial stiffness in subjects with type 2 diabetes. Diabetes. Conference: 69th Annual Meeting of the American Diabetes Association New Orleans, LA United States. 56. DeFronzo, R. A. and Prato, S. D. Insulin resistance and diabetes mellitus. Journal. of Diabetes & its Complications. 10(5):243-5, 1996 Sep-Oct. 57. Denton, C. P. Merkel PA, Furst DE, Khanna D, Emery P, Hsu VM, Silliman N, Streisand J, Powell J, Akesson A, Coppock J, Hoogen F, Herrick A, Mayes MD, Veale D, Haas J, Ledbetter S, Korn JH, Black CM, Seibold JR, Cat-192 Study Group, Scleroderma Clinical Trials Consortium. Recombinant human anti-transforming growth factor beta1 antibody therapy in systemic sclerosis: a multicenter, randomized, placebo-controlled phase I/II trial of CAT-192. Arthritis. and rheumatism. 56(1):323-33, 2007 Jan. 58. Dietrich, A.; Kioschis, P.; Monaco, A. P.; Gross, B.; Korn, B.; Williams, S. V.; Sheer, D.; Heitz, D.; Oberle, I.; Toniolo, D. and others. Molecular cloning and analysis of the fragile X region in man. Nucleic. Acids Research. 19(10):2567-72, 1991 May 25. 59. Dietrich, A.; Korn, B., and Poustka, A. Completion of the physical map of Xq28: the location of the gene for L1CAM on the human X chromosome. Mammalian. genome : official journal of the International Mammalian Genome Society. 3 (3) (pp 168-172), 1992. Date of Publication: 1992. 60. Dingemanse, J. Kneer J, Wallnofer A, Kettler R, Zurcher G, Koulu M, Korn A. Pharmacokinetic-pharmacodynamic interactions between two selective monoamine oxidase inhibitors: moclobemide and selegiline. Clinical. neuropharmacology. 19(5):399-414, 1996 Oct. 61. Dingemanse, J. Kneer J, Wallnofer A, Kettler R, Zurcher G, Koulu M, Korn A. Biochemical effects of high single doses of moclobemide in man: correlation with plasma concentrations. Psychopharmacology. Vol.106 Suppl, pp.S46-8, 1992. 62. Dittrich, B.; Buiting, K.; Korn, B.; Rickard, S.; Buxton, J.; Saitoh, S.; Nicholls R.D.; Poustka, A.; Winterpacht, A.; Zabel, B., and Horsthemke, B. Imprint switching on

WorkSafeBC Evidence-Based Practice Group January 2016 www.worksafebc.com/evidence Treating Mesothelioma: Reviewing Multiple Treatment Modalities 11

human chromosome 15 may involve alternative transcripts of the SNRPN gene. Nature. Genetics. 14 (2) (pp 163-170), 1996. Date of Publication: October 1996. 63. Dotta, F.; Censini, S.; van Halteren, A. G.; Marselli, L.; Masini, M.; Dionisi, S.; Mosca, F.; Boggi, U.; Muda, A. O.; Prato, S. D.; Elliott, J. F.; Covacci, A.; Rappuoli, R.; Roep, B. O., and Marchetti, P. Coxsackie B4 virus infection of beta cells and natural killer cell insulitis in recent-onset type 1 diabetic patients. Proceedings. of the National Academy of Sciences of the United States of America. 104(12):5115-20, 2007 Mar 20. 64. Eichhorst, S. T. ; Elser, B. ; Schick, M. ; Korn, B. ; Poustka, A. , and Krammer, P. H. . Engagement of pro- and antiapoptotic mechanisms in liver cells following administration of chemotherapeutic drugs revealed by microarray analysis. Journal. of Hepatology. 32(Supplement 2):79, 2000. 65. Eichler, H. G. Jung M, Kyrle PA, Rotter M, Korn A. Absence of interaction between tenoxicam and warfarin. European. journal of clinical pharmacology. 42(2):227-9, 1992. 66. Eichler, H. G. Jung M, Kyrle PA, Rotter M, Korn A. Rioprostil, a new prostaglandin E1 analogue does not affect glucose homeostasis in healthy volunteers. Archives. internationales de pharmacodynamie et de therapie. Vol.298, pp.288-92, 1989 Mar- Apr. 67. Eichler, H. G. Jung M, Kyrle PA, Rotter M, Korn A. The effect of a new specific alpha- amylase inhibitor on post-prandial glucose and insulin excursions in normal and Type 2 (non-insulin-dependent) diabetic patients. DIABETOLOGIA. 26(4):278-281, 1984. 68. Eickhoff, B.; Korn, B.; Schick, M.; Poustka, A., and van der Bosch, J. Normalization of array hybridization experiments in differential gene expression analysis. Nucleic. acids research. 27 (22) (pp e33), 1999. Date of Publication: 15 Nov 1999. 69. Elfant, A. B. Korn C, Mendez L, Pello MJ, Peikin SR. Recall of informed consent after endoscopic procedures. Diseases. of the colon and rectum. 38(1):1-3, 1995 Jan. 70. Elia, A.; Siegeli, M.; Steinmulle, A.; Von Deimling, A.; Lass, U.; Korn, B., and Mueller, W. Epigenetic silencing of death receptor 4 mediates TRAILresistance in gliomas. Acta. Neuropathologica. Conference: 54. Annual Meeting of the German Society of Neuropathology and Neuroanatomy, DGNN Dusseldorf Germany. Conference Start: 20090916 Conference End: 20090919. Conference Publication: (var.pagings). 118 (3) (pp 438), 2009. Date of Publication: September 2009. 71. Elias, A.; Siegelin, M. D.; Steinmuller, A.; von Deimling, A.; Lass, U.; Korn, B., and Mueller, W. Epigenetic silencing of death receptor 4 mediates tumor necrosis factor- related apoptosis-inducing ligand resistance in gliomas. Clinical. Cancer Research. 15(17):5457-65, 2009 Sep 1. 72. Faber and Korn. Erratum: (Biophysical Journal (November 1991) 60 (129)). Biophysical. Journal. 61 (3) (pp 835), 1992. Date of Publication: 1992. 73. Francis, F.; Hennig, S.; Korn, B.; Reinhardt, R.; De Jong, P.; Poustka, A.; Lehrach, H.; Rowe P.S.N.; Goulding J.N.; Summerfield, T.; Mountford, R.; Read A.P.; Popowska, E.; Pronicka, E.; Davies K.E.; O'Riordan J.L.H.; Econs M.J.; Nesbitt, T.; Drezner M.K.; Oudet, C.; Pannetier, S.; Hanauer, A.; Strom T.M.; Meindl, A.; Lorenz, B.; Cagnoli, M.; Mohnike K.L.; Murken, J., and Meitinger, T. A gene (PEX) with homologies to endopeptidases is mutated in patients with X-linked hypophosphatemic

WorkSafeBC Evidence-Based Practice Group January 2016 www.worksafebc.com/evidence Treating Mesothelioma: Reviewing Multiple Treatment Modalities 12

rickets. Nature. Genetics. 11 (2) (pp 130-136), 1995. Date of Publication: October 1995. 74. Gaab, M. R. Haubitz I, Brawanski A, Czech TH, Korn A. Acute effects of nimodipine on cerebral blood flow and intracranial pressure. Nimodipine. Pharmacology and Clinical Properties. 163-176p. 1984. 75. Gananca, F. F. Simas R, Gananca MM, Korn GP, , Dorigueto RS, et al. [Is it important to restrict head movement after Epley maneuver?]. Revista. Brasileira De Otorrinolaringologia. 71(6):764-8, 2005. 76. Gasic, S. Dudczak R, Korn A, Kleinbloesem C. ACE inhibition with cilazapril improves myocardial perfusion to the ischemic regions during exercise: a pilot study. Journal. of cardiovascular pharmacology. 15(2):227-32, 1990 Feb. 77. Gasic, S. Dudczak R, Korn A, Kleinbloesem C. [The effect of the calciumantagonist dimeditiapramine on thallium-201 myocardial perfusion during exercise in patients with coronary heart disease (author's transl)]. Wiener. klinische Wochenschrift. 92(8):284-90, 1980 Apr. 78. Gasic, S. Dudczak R, Korn A, Kleinbloesem C. Effect of calcium antagonists on basal and digitalis-dependent changes in splanchnic and systemic hemodynamics. Clinical. pharmacology and therapeutics. 41(4):460-6, 1987 Apr. 79. Gasic, S. Dudczak R, Korn A, Kleinbloesem C. Effects of ACE inhibition with cilazapril on splanchnic and systemic haemodynamics in man. British. journal of clinical pharmacology. Vol.27 Suppl 2, pp.225S-234S, 1989. 80. Gasic, S. Dudczak R, Korn A, Kleinbloesem C. Effect of diclofensine, a novel antidepressant, on peripheral adrenergic function. CLIN. PHARMACOL THER. 39(5):582-585, 1986. 81. Gasic, S. Dudczak R, Korn A, Kleinbloesem C. Cardiocirculatory effects of moclobemide (Ro 11-1163), a new reversible, a short-acting MAO-inhibitor with preferential type A inhibition, in healthy volunteers and depressive patients. European. journal of clinical pharmacology. 25(2):173-7, 1983. 82. Gasic, S. Dudczak R, Korn A, Kleinbloesem C. Cardiocirculatory effects of Ro 11-2465, a selective 5-HT (serotonin) uptake inhibitor, in healthy volunteers. European. journal of clinical pharmacology. 21(5):357-61, 1982. 83. Gedeon, A. K. ; Baker, E. ; Robinson, H. ; Partington, M. W. ; Gross, B. ; Manca, A. ; Korn, B. ; Poustka, A. ; Yu, S. ; Sutherland, G. R. , and Mulley, J. C. . Fragile X syndrome without CCG amplification has an FMR1 deletion. Nature. Genetics. 1(5):341-344, 1992. 84. Ghezala, G. Ait ; Gosset, P. ; Rabatel, N. ; Korn, B. ; Yaspo, M. L. ; Poutska, A. M. ; Lehrach, H. ; Sinet, P. M. , and Creau, N. . Integrated physical and transcriptional map of the Down syndrome Chromosome Region (DCR) between D21S55 and ERG. Cytogenetics. & Cell Genetics. 79(1-2):36, 1997. 85. GlaxoSmithKline Vaccine HPV-007 Study Group, Romanowski B, de Borba PC, Naud PS, Roteli-Martins CM, De Carvalho NS, Teixeira JC, Aoki F, Ramjattan B, Shier RM, Somani R, Barbier S, Blatter MM, Chambers C, Ferris D, Gall SA, Guerra FA, Harper DM, Hedrick JA, Henry DC, Korn AP, Kroll R, Moscicki AB, Rosenfeld WD, Sullivan BJ, Thoming CS, Tyring SK, Wheeler CM, Dubin G, Schuind A, Zahaf T, Greenacre M, Sgriobhadair A. Sustained efficacy and immunogenicity of the human papillomavirus

WorkSafeBC Evidence-Based Practice Group January 2016 www.worksafebc.com/evidence Treating Mesothelioma: Reviewing Multiple Treatment Modalities 13

(HPV)-16/18 AS04-adjuvanted vaccine: analysis of a randomised placebo-controlled trial up to 6.4 years. Lancet. 374(9706):1975-85, 2009 Dec. 86. Gloriam D.E.; Orchard, S.; Bertinetti, D.; Bjorling, E.; Bongcam-Rudloff, E.; Borrebaeck C.A.K.; Bourbeillon, J.; Bradbury A.R.M.; De Daruvar, A.; Dubel, S.; Frank, R.; Gibson T.J.; Gold, L.; Haslam, N.; Herberg F.W.; Hiltke, T.; Hoheisel J.D.; Kerrien, S.; Koegl, M.; Konthur, Z.; Korn, B.; Landegren, U.; Montecchi-Palazzi, L.; Palcy, S.; Rodriguez, H.; Schweinsberg, S.; Sievert, V.; Stoevesandt, O.; Taussig M.J.; Ueffing, M.; Uhlen, M.; Van Der Maarel, S.; Wingren, C.; Woollard, P.; Sherman D.J., and Hermjkob, H. A community standard format for the representation of protein affinity reagents. Molecular. and Cellular Proteomics. 9 (1) (pp 1-10), 2010. Date of Publication: January 2010. 87. Gordon, M. L. Lipton RB, Brown S-L, Nakraseive C, Russell M, Pollack SZ, Korn ML, Merriam A, Solomon S, Van PHM. Headache and cortisol responses to m- chlorophenylpiperazine are highly correlated. CEPHALALGIA. 13(6):400-405, 1993. 88. Gosset, P.; Ghezala, G. A.; Korn, B.; Yaspo, M. L.; Poutska, A.; Lehrach, H.; Sinet, P. M., and Creau, N. A new inward rectifier potassium channel gene (KCNJ15) localized on chromosome 21 in the Down syndrome chromosome region 1 (DCR1). Genomics. 44(2):237-41, 1997 Sep 1. 89. Gosset, P. ; Ghezala, G. Ait ; Korn, B. ; Yaspo, M. L. ; Poutska, A. ; Lehrach, H. ; Sinet, P. M. , and Creau, N. . Isolation of a new potassium inwardly rectifier channel in the d21S55-ERG region of chromosome 21, potentially involved in Down syndrome. Cytogenetics. & Cell Genetics. 77(SUPPL. 1):30, 1997. 90. Gosset, Philippe ; Ait Ghezala, G. ; Rabatel, N. ; Korn, B. ; Yaspo, M. L. ; Poutska, A. M. ; Lehrach, H. ; Sinet, P. M. , and Creau, N. . Integrated physical and transcriptional map of the Down syndrome chromosome region (DCR) between D21S55 and ERG. European. Journal of Human Genetics. 4(SUPPL. 1):9-10, 1996. 91. Gronniger, E.; Weber, B.; Heil, O.; Peters, N.; Stab, F.; Wenck, H.; Korn, B.; Winnefeld, M., and Lyko, F. Aging and chronic sun exposure cause distinct epigenetic changes in human skin. PLoS. genetics. 6 (5) (pp e1000971), 2010. Date of Publication: 2010. 92. Guentert, T. W. Tucker G, Korn A, Pfefen JP, Haefelfinger P, Schoerlin MP. Pharmacokinetics of moclobemide after single and multiple oral dosing with 150 milligrams 3 times daily for 15 days. Acta. Psychiatrica Scandinavica, Supplement. 82(360):91-93, 1990. 93. Gupta, S.; Zink, D.; Korn, B.; Vingron, M., and Haas S.A. Genome wide identification and classification of alternative splicing based on EST data. Bioinformatics. 20 (16) (pp 2579-2585), 2004. Date of Publication: 01 Nov 2004. 94. Gupta, S.; Zink, D.; Korn, B.; Vingron, M., and Haas S.A. Strengths and weaknesses of EST-based prediction of tissue-specific alternative splicing. BMC. Genomics. 5 , 2004. Article Number: 72. Date of Publication: 28 Sep 2004. 95. Gutjahr, C.; Murphy, D.; Lueking, A.; Koenig, A.; Janitz, M.; O'Brien, J.; Korn, B.; Horn, S.; Lehrach, H., and Cahill D.J. Mouse protein arrays from a TH1 cell cDNA library for antibody screening and serum profiling. Genomics. 85 (3) (pp 285-296), 2005. Date of Publication: March 2005. 96. Haller, F.; Zhang J.D.; Riazalhosseini, Y.; Ward, A.; Balwierz, A.; Korn, B.; Schaefer I.-M.; Cameron, S.; Ghadimi B.M.; Agaimy, A.; Fletcher J.A.; Hoheisel, J.; Wiemann,

WorkSafeBC Evidence-Based Practice Group January 2016 www.worksafebc.com/evidence Treating Mesothelioma: Reviewing Multiple Treatment Modalities 14

S., and SahinO.Ozgur. Large-scale DNA methylation profiling in gastrointestinal stromal tumors (GIST) reveals epigenetic regulation of SPP1 as an independent prognostic factor. Cancer. Research. Conference: 103rd Annual Meeting of the American Association for Cancer Research, AACR 2012 Chicago, IL United States. Conference Start: 20120331 Conference End: 20120404. Conference Publication: (var.pagings). 72 (8 SUPPL. 1) , 2012. Date of Publication: 15 Apr 2012. 97. Harper, D. M. Franco EL, Wheeler C, Ferris DG, Jenkins D, Schuind A, Zahaf T, Innis B, Naud P, De Carvalho NS, Roteli-Martins CM, Teixeira J, Blatter MM, Korn AP, Quint W, Dubin G, GlaxoSmithKline HPV Vaccine Study Group. Efficacy of a bivalent L1 virus-like particle vaccine in prevention of infection with human papillomavirus types 16 and 18 in young women: a randomised controlled trial. Lancet. 364(9447):1757- 65, 2004 Nov 13-19. 98. Hartmann, D. Korn A, Komjati M, Heinz G, Haefelfinger P, Defoin R, Waldhausl WK. Lack of effect of tenoxicam on dynamic responses to concurrent oral doses of glucose and glibenclamide. British. journal of clinical pharmacology. 30(2):245-52, 1990 Aug. 99. Heinz, G. Komjati M, Korn A, Waldhausl W. Reduction of postprandial blood glucose by the alpha-glucosidase inhibitor Miglitol (BAY m 1099) in type II diabetes. European. journal of clinical pharmacology. 37(1):33-6, 1989. 100. Heiss N.S.; Korn, B.; Rogner U.C., and Poustka, A. Generation of specific exon trap probes from YACs using Alu long-range PCR products. Methods. in Molecular and Cellular Biology. 5 (6) (pp 337-344), 1996. Date of Publication: 1996. 101. Heiss N.S.; Rogner U.C.; Kioschis, P.; Korn, B., and Poustka, A. Transcriptional mapping in a 700-kb region around the DXS52 locus in Xq28: Isolation of six novel transcripts and a novel ATPase isoform (hPMCA5). Genome. Research. 6 (6) (pp 478- 491), 1996. Date of Publication: 1996. 102. Hemmerling, A. Harrison W, Schroeder A, Park J, Korn A, Shiboski S, Cohen CR. Phase 1 dose-ranging safety trial of Lactobacillus crispatus CTV-05 for the prevention of bacterial vaginosis. Sexually. transmitted diseases. 36(9):564-9, 2009 Sep. 103. Hemmerling, A. Harrison W, Schroeder A, Park J, Korn A, Shiboski S, Cohen CR. Phase 2a study assessing colonization efficiency, safety, and acceptability of Lactobacillus crispatus CTV-05 in women with bacterial vaginosis. Sexually. transmitted diseases. 37(12):745-50, 2010 Dec. 104. Henderson, S. O. Acharya P, Kilaghbian T, Perez J, Korn CS, Chan LS. Use of heliox- driven nebulizer therapy in the treatment of acute asthma. Annals. of emergency medicine. 33(2):141-6, 1999 Feb. 105. Hetzer, G. Korn G. Effect of consumption of meals prepared with fluoridated salt on salivary fluoride levels . Caries. Research. 31(4):317, 1997. 106. Hiller, W. Kroymann R, Leibbrand R, Cebulla M, Korn H-J, Rief W, Fichter MM. Effects and Cost-Effectiveness Analysis of Inpatient Treatment for Somatoform Disorders. Fortschritte. der Neurologie-Psychiatrie. 72(3):136-46, 2004. 107. Hitzenberger, G. Korn A, Dorcsi M, Bauer P, Wohlzogen FX. [Controlled randomized double-blind study for the comparison of the treatment of patients with essential hypertension with homeopathic and with pharmacologically effective drugs]. Wiener. klinische Wochenschrift. 94(24):665-70, 1982 Dec. 108. Hitzenberger, G. Korn A, Dorcsi M, Bauer P, Wohlzogen FX. A controlled randomized double-blind cross-over study of the effects of antihypertensive pharmacotherapy and

WorkSafeBC Evidence-Based Practice Group January 2016 www.worksafebc.com/evidence Treating Mesothelioma: Reviewing Multiple Treatment Modalities 15

homeopathy in patients with essential hypertension. WIEN-KLIN-WOCHENSCHR. 94(24):665-670, 1982. 109. Hoff, C.; Seranski, P.; Mollenhauer, J.; Korn, B.; Detzel, T.; Reinhardt, R.; Ramser, J., and Poustka, A. Physical and transcriptional mapping of the 17p13.3 region that is frequently deleted in human cancer. Genomics. 70(1):26-33, 2000 Nov 15. 110. Hoff, C. ; Seranski, P. ; Detzel, T. ; Korn, B. ; Ramser, J. ; Reinhardt, R. ; Hamann, U. , and Poustka, A. . Construction of a physical and transcriptional map of human chromosome 17p13.3 to identify a new tumor suppressor gene implicated in breast cancer. American. Journal of Human Genetics. 65(4):A226, Oct., 1999. 111. Horsthemke, B. ; Dittrich, B. ; Korn, B. ; Poustka, A. , and Buiting, K. . A transcript from the putative imprinting center in the Prader-Willi/Angelman syndrome region. American. Journal of Human Genetics. 57(4 SUPPL.):A30, 1995. 112. Houde, R. W. Larouche Korn SJ. Parenteral meptazinol: a US clinical trial. Postgraduate. medical journal. Vol.61 Suppl 2, pp.17-22, 1985. 113. Imanishi, T.; Itoh, T.; O'Donovan, C.; Fukuchi, S.; Koyanagi K.O.; Barrero R.A.; Tamura, T.; Yamaguchi-Kabata, Y.; Tanino, M.; Yura, K.; Miyazaki, S.; Ikeo, K.; Homma, K.; Kasprzyk, A.; Nishikawa, T.; Hirakawa, M.; Thierry-Mieg, J.; Thierry- Mieg, D.; Ashurst, J.; Jia, L.; Nakao, M.; Thomas M.A.; Mulder, N.; Karavidopoulou, Y.; Jin, L.; Kim, S.; Yasuda, T.; Lenhard, B.; Eveno, E.; Suzuki, Y.; Yamasaki, C.; Takeda, J.; Gough, C.; Hilton, P.; Fujii, Y.; Sakai, H.; Tanaka, S.; Amid, C.; Bellgard, M.; Bonaldo M.F.; Bono, H.; Bromberg S.K.; Brookes A.J.; Bruford, E.; Carninci, P.; Chelala, C.; Couillault, C.; de Souza S.J.; Debily M.A.; Devignes M.D.; Dubchak, I.; Endo, T.; Estreicher, A.; Eyras, E.; Fukami-Kobayashi, K.; Gopinath G.R.; Graudens, E.; Hahn, Y.; Han, M.; Han Z.G.; Hanada, K.; Hanaoka, H.; Harada, E.; Hashimoto, K.; Hinz, U.; Hirai, M.; Hishiki, T.; Hopkinson, I.; Imbeaud, S.; Inoko, H.; Kanapin, A.; Kaneko, Y.; Kasukawa, T.; Kelso, J.; Kersey, P.; Kikuno, R.; Kimura, K.; Korn, B.; Kuryshev, V.; Makalowska, I.; Makino, T.; Mano, S.; Mariage-Samson, R.; Mashima, J.; Matsuda, H.; Mewes H.W.; Minoshima, S.; Nagai, K.; Nagasaki, H.; Nagata, N.; Nigam, R.; Ogasawara, O.; Ohara, O.; Ohtsubo, M.; Okada, N.; Okido, T.; Oota, S., and Ota, M. Integrative annotation of 21,037 human genes validated by full-length cDNA clones. PLoS. biology. 2 (6) (pp e162), 2004. Date of Publication: Jun 2004. 114. Imanishi, T.; Itoh, T.; Suzuki, Y.; O'Donovan, C.; Fukuchi, S.; Koyanagi, K. O.; Barrero, R. A.; Tamura, T.; Yamaguchi-Kabata, Y.; Tanino, M.; Yura, K.; Miyazaki, S.; Ikeo, K.; Homma, K.; Kasprzyk, A.; Nishikawa, T.; Hirakawa, M.; Thierry-Mieg, J.; Thierry-Mieg, D.; Ashurst, J.; Jia, L.; Nakao, M.; Thomas, M. A.; Mulder, N.; Karavidopoulou, Y.; Jin, L.; Kim, S.; Yasuda, T.; Lenhard, B.; Eveno, E.; Suzuki, Y.; Yamasaki, C.; Takeda, J.; Gough, C.; Hilton, P.; Fujii, Y.; Sakai, H.; Tanaka, S.; Amid, C.; Bellgard, M.; Bonaldo Mde, F.; Bono, H.; Bromberg, S. K.; Brookes, A. J.; Bruford, E.; Carninci, P.; Chelala, C.; Couillault, C.; de Souza, S. J.; Debily, M. A.; Devignes, M. D.; Dubchak, I.; Endo, T.; Estreicher, A.; Eyras, E.; Fukami-Kobayashi, K.; Gopinath, G. R.; Graudens, E.; Hahn, Y.; Han, M.; Han, Z. G.; Hanada, K.; Hanaoka, H.; Harada, E.; Hashimoto, K.; Hinz, U.; Hirai, M.; Hishiki, T.; Hopkinson, I.; Imbeaud, S.; Inoko, H.; Kanapin, A.; Kaneko, Y.; Kasukawa, T.; Kelso, J.; Kersey, P.; Kikuno, R.; Kimura, K.; Korn, B.; Kuryshev, V.; Makalowska, I.; Makino, T.; Mano, S.; Mariage-Samson, R.; Mashima, J.; Matsuda, H.; Mewes, H. W.; Minoshima, S.; Nagai, K.; Nagasaki, H.; Nagata, N.; Nigam, R.; Ogasawara, O.; Ohara, O.; Ohtsubo,

WorkSafeBC Evidence-Based Practice Group January 2016 www.worksafebc.com/evidence Treating Mesothelioma: Reviewing Multiple Treatment Modalities 16

M.; Okada, N.; Okido, T.; Oota, S.; Ota, M.; Ota, T.; Otsuki, T.; Piatier-Tonneau, D.; Poustka, A.; Ren, S. X.; Saitou, N.; Sakai, K.; Sakamoto, S.; Sakate, R.; Schupp, I.; Servant, F.; Sherry, S.; Shiba, R.; Shimizu, N.; Shimoyama, M.; Simpson, A. J.; Soares, B.; Steward, C.; Suwa, M.; Suzuki, M.; Takahashi, A.; Tamiya, G.; Tanaka, H.; Taylor, T.; Terwilliger, J. D.; Unneberg, P.; Veeramachaneni, V.; Watanabe, S.; Wilming, L.; Yasuda, N.; Yoo, H. S.; Stodolsky, M.; Makalowski, W.; Go, M.; Nakai, K.; Takagi, T.; Kanehisa, M.; Sakaki, Y.; Quackenbush, J.; Okazaki, Y.; Hayashizaki, Y.; Hide, W.; Chakraborty, R.; Nishikawa, K.; Sugawara, H.; Tateno, Y.; Chen, Z.; Oishi, M.; Tonellato, P.; Apweiler, R.; Okubo, K.; Wagner, L.; Wiemann, S.; Strausberg, R. L.; Isogai, T.; Auffray, C.; Nomura, N.; Gojobori, T., and Sugano, S. Integrative annotation of 21,037 human genes validated by full-length cDNA clones.[Erratum appears in PLoS Biol. 2004 Jul;2(7):e256]. Plos. Biology. 2(6):e162, 2004 Jun. 115. Itzel, T.; Scholz, P.; Krupp, M.; Marquardt J.U.; Becker, D.; Staib, F.; Korn, B.; Galle P.R., and Teufel, A. Bioinformatics integration of oncogenetic microarray meta- analysis, guilt-of-profiling, and guilt-of-association strategies for the identification of novel co-regulated oncogenetic networks, novel oncogenes, and prognostic target gene signatures in HCC. Hepatology. Conference: 63rd Annual Meeting of the American Association for the Study of Liver Diseases: The Liver Meeting 2012 Boston, MA United States. Conference Start: 20121109 Conference End: 20121113. Conference Publication: (var.pagings). 56 (pp 625A), 2012. Date of Publication: October 2012. 116. Jakobs, A.; Himstedt, F.; Funk, M.; Korn, B.; Gaestel, M., and Niedenthal, R. Ubc9 fusion-directed SUMOylation identifies constitutive and inducible SUMOylation. Nucleic. Acids Research. 35(17):e109, 2007. 117. Jakobs, A.; Koehnke, J.; Himstedt, F.; Funk, M.; Korn, B.; Gaestel, M., and Niedenthal, R. Ubc9 fusion-directed SUMOylation (UFDS): a method to analyze function of protein SUMOylation. Nature. Methods. 4(3):245-50, 2007 Mar. 118. Janik, J. E. Miller LL, Korn EL, Stevens D, Curti BD, Smith JW, Sznol M, Conlon KC, Sharfman W, Urba WJ, Gause BL, Longo DL. A prospective randomized phase II trial of GM-CSF priming to prevent topotecan-induced neutropenia in chemotherapy-naive patients with malignant melanoma or renal cell carcinoma. Blood. 97(7):1942-6, 2001 Apr. 119. Jones K.A.; Black D.M.; Brown M.A.; Griffiths B.L.; Nicolai H.M.; Chambers J.A.; Bonjardim, M.; Xu C.-F.; Boyd, M.; McFarlane, R.; Korn, B.; Poustka, A.; North M.A.; Schalkwyk, L.; Lehrach, H., and Solomon, E. The detailed characterisation of a 400 kb cosmid walk in the BRCA1 region: Identification and localisation of 10 genes including a dual specificity phosphatase. Human. Molecular Genetics. 3 (11) (pp 1927-1934), 1994. Date of Publication: 1994. 120. Kane, M.; Korn, B.; Saukkonen, J.; McDonald, C.; Walsh, C.; Waters, R.; McLaughlin A.M., and Keane, J. Barriers to accepting &completing Latent Tuberculosis Infection treatment. Irish. Medical Journal. 106 (7) , 2013. Date of Publication: July - August 2013. 121. Kappos, L. Antel J, Comi G, Montalban X, O'Connor P, Polman CH, Haas T, Korn AA, Karlsson G, Radue EW, FTY720 D2201 Study Group. Oral fingolimod (FTY720) for

WorkSafeBC Evidence-Based Practice Group January 2016 www.worksafebc.com/evidence Treating Mesothelioma: Reviewing Multiple Treatment Modalities 17

relapsing multiple sclerosis. The. New England journal of medicine. 355(11):1124-40, 2006 Sep. 122. Karande, V. C. Korn A, Morris R, Rao R, Balin M, Rinehart J, Dohn K, Gleicher N. Prospective randomized trial comparing the outcome and cost of in vitro fertilization with that of a traditional treatment algorithm as first-line therapy for couples with infertility. Fertility. and sterility. 71(3):468-75, 1999 Mar. 123. Karande, V. Korn A, Morris R, Rao R, Balin M. The continous outcome and cost evaluation of a prospective randomised trial of in vitro fertilization (IVF) versus a traditional treatment algorithm as first choice infertility treatment. Fertility. & Sterility. 70(3):S171, 1998. 124. Karande, V. Korn A, Morris R, Rao R, Balin M. A prospective randomized trial, assessing outcome and cost of IVF as a first choice treatment versus a traditional infertility treatment algorithm. Fertility. & Sterility. S42p. 1997. 125. Kelemen, K.; Kristen, A.; Korn, B.; Bikou, O.; Lugenbiel, P.; Becker, F.; Thomas, D.; A. Katus, H., and Bauer, A. Gene expression profiling in cardiac amyloidosis reveals molecular links to ventricular arrhythmia. Heart. Rhythm. Conference: 32nd Annual Scientific Sessions of the Heart Rhythm Society, Heart Rhythm San Francisco, CA United States. 126. Kennedy, B.; O'Connor, B.; Korn, B.; Gibbons, N.; O'Connor, T., and Keane, J. Multi- drug resistant tuberculosis: experiences of two tertiary referral centres. Irish. Medical Journal. 104(6):182-5, 2011 Jun. 127. Kennedy, B.; O'Connor, B.; Korn, B.; Lyons, O.; Gargoum, F.; Gibbons, N.; O'Connor, T., and Keane J.M. Multi-drug resistant tuberculosis; early experiences of two irish tertiary referral centres. American. Journal of Respiratory and Critical Care Medicine. Conference: American Thoracic Society International Conference, ATS 2010 New Orleans, LA United States. 128. Khanna, D. Clements PJ, Furst DE, Korn JH, Ellman M, Rothfield N, Wigley FM, Moreland LW, Silver R, Kim YH, Steen VD, Firestein GS, Kavanaugh AF, Weisman M, Mayes MD, Collier D, Csuka ME, Simms R, Merkel PA, Medsger TA, Sanders ME, Maranian P, Seibold JR, Relaxin Investigators and the Scleroderma Clinical Trials Consortium. Recombinant human relaxin in the treatment of systemic sclerosis with diffuse cutaneous involvement: a randomized, double-blind, placebo-controlled trial. Arthritis. and rheumatism. 60(4):1102-11, 2009 Apr. 129. Khanna, D. Clements PJ, Furst DE, Korn JH, Ellman M, Rothfield N, Wigley FM, Moreland LW, Silver R, Kim YH, Steen VD, Firestein GS, Kavanaugh AF, Weisman M, Mayes MD, Collier D, Csuka ME, Simms R, Merkel PA, Medsger TA, Sanders ME, Maranian P, Seibold JR, Responsiveness of the SF-36 and the Health Assessment Questionnaire Disability Index in a systemic sclerosis clinical trial. The. Journal of rheumatology. 32(5):832-40, 2005 May. 130. Kioschis, P.; Rogner U.C.; Pick, E.; Klauck S.M.; Heiss, N.; Sebenhaar, R.; Korn, B.; Coy J.F.; Laporte, J.; Liechti-Gallati, S., and Poustka, A. A 900-kb cosmid contig and 10 new transcripts within the candidate region for myotubular myopathy (MTM1). Genomics. 33 (3) (pp 365-373), 1996. Date of Publication: 01 May 1996. 131. Kittler, R.; Putz, G.; Pelletier, L.; Poser, I.; Heninger, A. K.; Drechsel, D.; Fischer, S.; Konstantinova, I.; Habermann, B.; Grabner, H.; Yaspo, M. L.; Himmelbauer, H.; Korn, B.; Neugebauer, K.; Pisabarro, M. T., and Buchholz, F. An endoribonuclease-

WorkSafeBC Evidence-Based Practice Group January 2016 www.worksafebc.com/evidence Treating Mesothelioma: Reviewing Multiple Treatment Modalities 18

prepared siRNA screen in human cells identifies genes essential for cell division. Nature. 432(7020):1036-40, 2004 Dec 23. 132. Kittler, R.; Surendranath, V.; Heninger, A. K.; Slabicki, M.; Theis, M.; Putz, G.; Franke, K.; Caldarelli, A.; Grabner, H.; Kozak, K.; Wagner, J.; Rees, E.; Korn, B.; Frenzel, C.; Sachse, C.; Sonnichsen, B.; Guo, J.; Schelter, J.; Burchard, J.; Linsley, P. S.; Jackson, A. L.; Habermann, B., and Buchholz, F. Genome-wide resources of endoribonuclease-prepared short interfering RNAs for specific loss-of-function studies. Nature. Methods. 4(4):337-44, 2007 Apr. 133. Koch, M. Korn A, Lueck R, Becker T, Klempnauer J, Nashan B. Long term results of basiliximab in renal transplantation [abstract no:1020]. American. Journal of Transplantation. 2(Suppl 3):395, 2002. 134. Konkimalla, V. B.; Blunder, M.; Korn, B.; Soomro, S. A.; Jansen, H.; Chang, W.; Posner, G. H.; Bauer, R., and Efferth, T. Effect of artemisinins and other endoperoxides on nitric oxide-related signaling pathway in RAW 264.7 mouse macrophage cells. Nitric. Oxide. 19(2):184-91, 2008 Sep. 135. Konkimalla, V. B. ; Blunder, M. ; Thedinga, E. ; Korn, B. ; Bauer, R. , and Efferth, T. . Artemisinin derivatives induce generation of nitric oxide and reactive oxygen species in cell lines of hematopoietic origin. Nitric. Oxide. 17(Suppl. 1):S21-S22, 2007. 136. Korn; Braghetto; Burdiles, and Csendes. Cardiomyotomy in achalasia: Which fibers do we cut?. Diseases. of the Esophagus. 13 (2) (pp 104-107), 2000. Date of Publication: 2000. 137. Korn; Stagnaro-Green, and Rose. Erratum: (Academic Medicine (October 2001) (530)). Academic. Medicine. 77 (3) (pp 246), 2002. Date of Publication: 2002. 138. Korn, A. Eichler HG, Fischbach R, Gasic S. Moclobemide, a new reversible MAO inhibitor - interaction with tyramine and tricyclic antidepressants in healthy volunteers and depressive patients. PSYCHOPHARMACOLOGY. 88(2):153-157, 1986. 139. Korn, A. Eichler HG, Fischbach R, Gasic S. A drug interaction study of ceftriaxone and frusemide in healthy volunteers. International. journal of clinical pharmacology, therapy, and toxicology. 24(5):262-4, 1986 May. 140. Korn, A. Eichler HG, Fischbach R, Gasic S. Long-term experience with Sandimmun Neoral: results in de novo and stable renal transplant patients after 24-month treatment. The German Neoral Study Group. Transplantation. proceedings. 29(7):2945-7, 1997 Nov. 141. Korn, A. Eichler HG, Fischbach R, Gasic S. Tyramine pressor sensitivity in healthy subjects during combined treatment with moclobemide and selegiline. European. journal of clinical pharmacology. 49(4):273-8, 1996. 142. Korn, B. Pharmaceutical services. Hospitals. 44(Apr 16): p 28. 1970. 143. Korn, B. Prescription of controlled substances. Hospitals. 45(Nov 16): p 16. 1971. 144. Korn, B. Unsolicited drug samples. Hospitals. 46(Jun 1): p 16. 1972. 145. Korn, B.; Sedlacek, Z.; Manca, A.; Kioschis, P.; Konecki, D.; Lehrach, H., and Poustka, A. A strategy for the selection of transcribed sequences in the Xq28 region. Human. Molecular Genetics. 1(4):235-42, 1992 Jul. 146. Korn, B.; Tracey, G., and O'Donnell, R. Transcending the divide: A case study of interdisciplinary and multi centre shared care. Irish. Journal of Medical Science. Conference: Irish Thoracic Society Annual Scientific Meeting 2011 Co. Dublin Ireland.

WorkSafeBC Evidence-Based Practice Group January 2016 www.worksafebc.com/evidence Treating Mesothelioma: Reviewing Multiple Treatment Modalities 19

147. Korn, B.; Weissman, S.; Werner, T., and Gardiner, K. Report on the tenth international workshop on the identification of transcribed sequences 2000. Cytogenetics. and Cell Genetics. 92 (1-2) (pp 49-58), 2001. Date of Publication: 2001. 148. Korn, B. and Poustka, A. . Transcriptional mapping by direct cDNA selection: From Xq28 to the entire X chromosome. American. Journal of Human Genetics. 55(3 SUPPL.):A262, 1994. 149. Korn, E. L. Baumrind S. A randomized orthodontic clinical trial with clinician-preferred treatment . Journal. of Dental Research. 68(Spec Iss [AADR Abstracts]):385, Abstract no: 1631, 1989. 150. Korn, G. W. The use of an ion-exchange resin in the control of pre-eclampsia. Journal. of Obstetrics and Gynaecology of the British Commonwealth. Vol.63, pp.686-689, 1956. 151. Korn, H. V. Yu J, Ohlow MA, Huegl B, Schulte W, Wagner A, Wassmer G, Gruene S, Petek O, Lauer B. Interventional therapy of bifurcation lesions: a TIMI flow-guided concept to treat side branches in bifurcation lesions--a prospective randomized clinical study (Thueringer bifurcation study, THUEBIS study as pilot trial). Circulation. Cardiovascular interventions. 2(6):535-42, 2009 Dec. 152. Korn, J. H. Mayes M, Matucci Cerinic M, Rainisio M, Pope J, Hachulla E, Rich E, Carpentier P, Molitor J, Seibold JR, Hsu V, Guillevin L, Chatterjee S, Peter HH, Coppock J, Herrick A, Merkel PA, Simms R, Denton CP, Furst D, Nguyen N, Gaitonde M, Black C. Digital ulcers in systemic sclerosis: prevention by treatment with bosentan, an oral endothelin receptor antagonist. Arthritis. and rheumatism. 50(12):3985-93, 2004 Dec. 153. Korn, L. Logsdon RG, Polissar NL, Gomez-Beloz A, Waters T, Ryser R. A randomized trial of a CAM therapy for stress reduction in American Indian and Alaskan Native family caregivers. The. Gerontologist. 49(3):368-77, 2009 Jun. 154. Korn, N. A. A comparison of the postoperative bacteremias induced following different periodontal procedures. Journal. of Periodontology. 33(3):1962. 155. Korn, S. Buhl R. Efficacy of a fixed combination of ciclesonide and formoterol: the EXCITED-study. Respiratory. medicine. 106(1):57-67, 2012 Jan. 156. Korn, S. Buhl R. Indacaterol once-daily provides superior efficacy to salmeterol: A 12- week trial . European. Respiratory Society Annual Congress, Barcelona, Spain, September 18-22. [P1226]p. 2010. 157. Korn, S. Buhl R. Indacaterol once-daily provides superior efficacy to salmeterol twice- daily in COPD: a 12-week study. Respiratory. medicine. 105(5):719-26, 2011 May. 158. Korn, S. Buhl R. Comparison of rofecoxib and oxycodone plus acetaminophen in the treatment of acute pain: a randomized, double-blind, placebo-controlled study in patients with moderate to severe postoperative pain in the third molar extraction model. Clinical. therapeutics. 26(5):769-78, 2004 May. 159. Kovarik, J. Breidenbach T, Gerbeau C, Korn A, Schmidt AG, Nashan B. Disposition and immunodynamics of basiliximab in liver allograft recipients. Clinical. pharmacology and therapeutics. 64(1):66-72, 1998 Jul. 160. Kovarik, J. M. Korn A, Chodoff L. Within-patient controlled assessment of the influence of basiliximab on cyclosporine in pediatric de novo renal transplant recipients. Transplantation. proceedings. 33(7-8):3172-3, 2001 Nov-Dec.

WorkSafeBC Evidence-Based Practice Group January 2016 www.worksafebc.com/evidence Treating Mesothelioma: Reviewing Multiple Treatment Modalities 20

161. Kovarik, J. M. Korn A, Chodoff L. A population pharmacokinetic screen to identify demographic-clinical covariates of basiliximab in liver transplantation. Clinical. pharmacology and therapeutics. 69(4):201-9, 2001 Apr. 162. Kowoll, R. Korn F, Thomschke U, Polat M, Zimmermann E, Welsch H. Assessment of psychological stress during a daily 8-hour stay in a hypobaric altitude chamber for 21 nights. International. Journal of Sports Medicine. 23(Suppl):S80, 2002. 163. Kuryshev V.Yu.; Vorobyov, E.; Zink, D.; Schmitz, J.; Rozhdestvensky T.S.; Munstermann, E.; Ernst, U.; Wellenreuther, R.; Moosmayer, P.; Bechtel, S.; Schupp, I.; Horst, J.; Korn, B.; Poustka, A., and Wiemann, S. An anthropoid-specific segmental duplication on human chromosome 1q22. Genomics. 88 (2) (pp 143-151), 2006. Date of Publication: August 2006. 164. Landers, S.; McLaughlin A.M.; Keane, J.; Korn, B.; Kelly, F., and Gibbons, N. Goodii Gosh; The emergence of pneumonia due to mycobacterium goodii in an irish adult male. Irish. Journal of Medical Science. Conference: Irish Thoracic Society Annual Scientific Meeting 2011 Co. Dublin Ireland. 165. Landers, S.; McLaughlin A.M.; Keane, J.; Korn, B.; Kelly, F.; Scully, M.; Watters, R., and Lyons F.E. Extensive transmission of the beijing strain of mycobacterium tuberculosis in an irish prison. Irish. Journal of Medical Science. Conference: Irish Thoracic Society Annual Scientific Meeting 2011 Co. Dublin Ireland. 166. Langlais, C.; Guilleaume, B.; Wermke, N.; Scheuermann, T.; Ebert, L.; LaBaer, J., and Korn, B. A systematic approach for testing expression of human full-length proteins in cell-free expression systems. BMC. Biotechnology. 7:64, 2007. 167. Larouche, S. J. Block G, Raskin S, Ahrens S, Korn S. Controlled trial of cyclobenzaprine for acute musculoskeletal spasm. Clin. Pharmacol Ther. Vol.65, pp.120, 1999. 168. Lawen, J. G. Davies EA, Mourad G, Oppenheimer F, Molina MG, Rostaing L, Wilkinson AH, Mulloy LL, Bourbigot BJ, Prestele H, Korn A, Girault D, Simulect International Study Group. Randomized double-blind study of immunoprophylaxis with basiliximab, a chimeric anti-interleukin-2 receptor monoclonal antibody, in combination with mycophenolate mofetil-containing triple therapy in renal transplantation. Transplantation. 75(1):37-43, 2003 Jan. 169. Lawlor, M.; Kealy, S.; Agnew, M.; Korn, B.; Quinn, J.; Cassidy, C.; Silke, B.; O'Connell, F., and O'Donnell, R. Early discharge care with ongoing follow-up support may reduce hospital readmissions in COPD. International. Journal of Copd. 4:55-60, 2009. 170. Limburg, P. J. Wei W, Ahnen DJ, Qiao Y, Hawk ET, Wang G, Giffen CA, Wang G, Roth MJ, Lu N, Korn EL, Ma Y, Caldwell KL, Dong Z, Taylor PR, Dawsey SM. Randomized, placebo-controlled, esophageal squamous cell cancer chemoprevention trial of selenomethionine and celecoxib. Gastroenterology. 129(3):863-73, 2005 Sep. 171. Lucchesi, D.; Pucci, L.; Storti, E.; Ghadoni, L.; Russo, E.; Bianchi, C.; Daniele, A.; Taddei, S.; Miccoli, R.; Penno, G., and Prato S.D. Early vascular alteration in subjects with normal, impaired, and diabetic glucose tolerance. Diabetes. Conference: 69th Annual Meeting of the American Diabetes Association New Orleans, LA United States. Conference Start: 20090605 Conference End: 20090609. Conference Publication: (var.pagings). 58 , 2009. Date of Publication: 2009.

WorkSafeBC Evidence-Based Practice Group January 2016 www.worksafebc.com/evidence Treating Mesothelioma: Reviewing Multiple Treatment Modalities 21

172. Malerczyk, V. Badian M, Korn A, Lehr KH, Waldhausl W. Dose linearity assessment of glimepiride (Amaryl) tablets in healthy volunteers. Drug. metabolism and drug interactions. 11(4):341-57, 1994. 173. Malerczyk, V. Badian M, Korn A, Lehr KH, Waldhausl W. Relative bioavailability of ofloxacin tablets in comparison to oral solution. Current. medical research and opinion. 10(8):514-20, 1987. 174. Mann, B. D. Storm FK, Morton DL, Bertelsen CA, Korn EL, Kaiser LR, Kern DH. Predictability of response to clinical thermochemotherapy by the clonogenic assay. Cancer. 52(8):1389-94, 1983 Oct. 175. Marczynski, B. Merget R, Teschner B, Korn M, Rabstein S, Bruning T. Changes in low molecular weight DNA fragmentation in white blood cells after diisocyanate exposure of workers. Archives. of Toxicology. 77(8):470-6, 2003. 176. Margolis, K. L. Poland GA, Nichol KL, MacPherson DS, Meyer JD, Korn JE, Lofgren RP. Frequency of adverse reactions after influenza vaccination. American. Journal of Medicine. 88(1):27-30, 1990. 177. Martin-Subero J.I.; Kreuz, M.; Bibikova, M.; Bentink, S.; Ammerpohl, O.; Wickham- Garcia, E.; Rosolowski, M.; Richter, J.; Lopez-Serra, L.; Ballestar, E.; Berger, H.; Agirre, X.; Bernd H.-W.; Calvanese, V.; Cogliatti S.B.; Drexler H.G.; Fan J.-B.; Fraga M.F.; Hansmann M.L.; Hummel, M.; Klapper, W.; Korn, B.; Kuppers, R.; MacLeod R.F.; Moller, P.; Ott, G.; Pott, C.; Prosper, F.; Rosenwald, A.; Schwaenen, C.; Schubeler, D.; Seifert, M.; Sturzenhofecker, B.; Weber, M.; Wessendorf, S.; Loeffler, M.; Trumper, L.; Stein, H.; Spang, R.; Esteller, M.; Barker, D.; Hasenclever, D., and Siebert, R. New insights into the biology and origin of mature aggressive B-cell lymphomas by combined epigenomic, genomic, and transcriptional profiling. Blood. 113 (11) (pp 2488-2497), 2009. Date of Publication: 12 Mar 2009. 178. Matl, I. Bachleda P, Lao M, Michalsky R, Navratil P, Treska V, Prestele H, Matthisson M, Korn A. Safety and efficacy of an alternative basiliximab (Simulect) regimen after renal transplantation: administration of a single 40-mg dose on the first postoperative day in patients receiving triple therapy with azathioprine. Transplant. international : official journal of the European Society for Organ Transplantation. 16(1):45-52, 2003 Jan. 179. Matl, I. Bachleda P, Lao M, Michalsky R, Navratil P, Treska V, Prestele H, Matthisson M, Korn A. Basiliximab can be administered safely and effectively in a single dose on day 1 postrenal transplantation in patients receiving triple therapy with azathioprine. Transplantation. proceedings. 33(7-8):3205-6, 2001 Nov-Dec. 180. Matucci-Cerinic, M. Denton CP, Furst DE, Mayes MD, Hsu VM, Carpentier P, Wigley FM, Black CM, Fessler BJ, Merkel PA, Pope JE, Sweiss NJ, Doyle MK, Hellmich B, Medsger TA, Morganti A, Kramer F, Korn JH, Seibold JR. Bosentan treatment of digital ulcers related to systemic sclerosis: results from the RAPIDS-2 randomised, double- blind, placebo-controlled trial. Annals. of the rheumatic diseases. 70(1):32-8, 2011 Jan. 181. McCarthy L.J. and Korn, B. A problem in communication. Transfusion. 24 (2) (pp 184), 1984. Date of Publication: 1984 Mar-Apr. 182. McNamee, H. B. Mendelson JH, Korn J. Fenmetozole in acute alcholol intoxication in man. Clinical. pharmacology and therapeutics. 17(6):735-7, 1975 Jun.

WorkSafeBC Evidence-Based Practice Group January 2016 www.worksafebc.com/evidence Treating Mesothelioma: Reviewing Multiple Treatment Modalities 22

183. Meder, B.; Haas, J.; Keller, A.; Heid, C.; Just, S.; Borries, A.; Boisguerin, V.; Scharfenberger-Schmeer, M.; Stahler, P.; Beier, M.; Weichenhan, D.; Strom, T.; Pfeufer, A.; Korn, B.; Katus H.A., and Rottbauer, W. Targeted next-generation sequencing for the molecular genetic diagnostics of cardiomyopathies. Circulation. Cardiovascular Genetics. 4 (2) (pp 110-122), 2011. Date of Publication: April 2011. 184. Mehlisch, D. R. Jasper RD, Brown P, Korn SH, McCarroll K, Murakami AA. Comparative study of ibuprofen lysine and acetaminophen in patients with postoperative dental pain. Clinical. therapeutics. 17(5):852-60, 1995 Sep-Oct. 185. Mendrzyk, F.; Korshunov, A.; Toedt, G.; Schwarz, F.; Korn, B.; Joos, S.; Hochhaus, A.; Schoch, C.; Lichter, P., and Radlwimmer, B. Isochromosome breakpoints on 17p in medulloblastoma are flanked by different classes of DNA sequence repeats. Genes. Chromosomes and Cancer. 45 (4) (pp 401-410), 2006. Date of Publication: April 2006. 186. Merkel, P. A. Silliman NP, Denton CP, Furst DE, Khanna D, Emery P, Hsu VM, Streisand JB, Polisson RP, Akesson A, Coppock J, van den Hoogen F, Herrick A, Mayes MD, Veale D, Seibold JR, Black CM, Korn JH, CAT-192 Research Group, Scleroderma Clinical Trials Consortium. Validity, reliability, and feasibility of durometer measurements of scleroderma skin disease in a multicenter treatment trial. Arthritis. and rheumatism. 59(5):699-705, 2008 May. 187. Miller, L. L. Korn EL, Stevens DS, Janik JE, Gause BL, Kopp WC, Holmlund JT, Curti BD, Sznol M, Smith JW, Urba WJ, Donegan SE, Watson TM, Longo DL. Abrogation of the hematological and biological activities of the interleukin-3/granulocyte- macrophage colony-stimulating factor fusion protein PIXY321 by neutralizing anti- PIXY321 antibodies in cancer patients receiving high-dose carboplatin. Blood. 93(10):3250-8, 1999 May. 188. Mollenhauer, J.; Wiemann, S.; Scheurlen, W.; Korn, B.; Hayashi, Y.; Wilgenbus K.K.; Von Deimling, A., and Poustka, A. DMBT1, a new member of the SRCR superfamily, on chromosome 10q25.3-26.1 is deleted in malignant brain tumours. Nature. Genetics. 17 (1) (pp 32-39), 1997. Date of Publication: 1997. 189. Mollenhauer, J. ; Wiemann, S. ; Scheurlen, W. ; Korn, B. ; Hayashi, Y. ; Von Deimling, A. , and Poustka, A. . DMBT1, a new member of the SRCR superfamily, is deleted in malignant brain tumors. American. Journal of Human Genetics. 61(4 SUPPL.):A75, Oct., 1997. 190. Moreland, L. Gugliotti R, King K, Chase W, Weisman M, Greco T, Fife R, Korn J, Simms R, Tesser J, Hillson J, Caldwell J, Schnitzer T, Lyons D, Schwertschlag U. Results of a phase-I/II randomized, masked, placebo-controlled trial of recombinant human interleukin-11 (rhIL-11) in the treatment of subjects with active rheumatoid arthritis. Arthritis. research. 3(4):247-52, 2001. 191. Nadia, D. ; Chamoun, Z. ; Charron, G. ; Lopes, C. ; Korn, B. ; Yaspo, M. L. ; Sinet, P. M. ; Bloch, B. , and Delabar, J. M. . Down Syndrome Critical Region contains a gene, homologous to Drosophila sim, expressed during rat and human central nervous system development. Cytogenetics. & Cell Genetics. 79(1-2):41, 1997. 192. Nadia, Dahmane ; Lopes, C. ; Dufresne-Zacharia, M. C. ; Chamoun, Z. ; Korn, B. ; Poutska, A. M. ; Yaspo, M. L. ; Lehrach, H. ; Sinet, P. M. , and Delabar, J. M. . Transcriptional mapping in the Down syndrome chromosomal region reveals new

WorkSafeBC Evidence-Based Practice Group January 2016 www.worksafebc.com/evidence Treating Mesothelioma: Reviewing Multiple Treatment Modalities 23

transcripts and transcripts homologous to drosophila sim and mnb. American. Journal of Human Genetics. 59(4 SUPPL.):A91, 1996. 193. Natelson, B. H. Cheu J, Hill N, Bergen M, Korn L, Denny T, Dahl K. Single-blind, placebo phase-in trial of two escalating doses of selegiline in the chronic fatigue syndrome. Neuropsychobiology. 37(3):150-4, 1998. 194. Nelson, S. L. Brahim JS, Korn SH, Greene SS, Suchower LJ. Comparison of single- dose ibuprofen lysine, acetylsalicylic acid, and placebo for moderate-to-severe postoperative dental pain. Clinical. therapeutics. 16(3):458-65, 1994 May-Jun. 195. Neuhaus, P. Clavien PA, Kittur D, Salizzoni M, Rimola A, Abeywickrama K, Ortmann E, Chodoff L, Hall M, Korn A, Nashan B, CHIC 304 International Liver Study Group. Improved treatment response with basiliximab immunoprophylaxis after liver transplantation: results from a double-blind randomized placebo-controlled trial. Liver. transplantation : official publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society. 8(2):132-42, 2002 Feb. 196. Neumayer, H. H. Paradis K, Korn A, Jean C, Fritsche L, Budde K, Winkler M, Kliem V, Pichlmayr R, Hauser IA, Burkhardt K, Lison AE, Barndt I, Appel-Dingemanse S. Entry- into-human study with the novel immunosuppressant SDZ RAD in stable renal transplant recipients. British. journal of clinical pharmacology. 48(5):694-703, 1999 Nov. 197. Newkirk, T. ; Flood, A. ; Bender, K. ; Collins, R. ; Fleckles, J. , And Korn, B. . Intravenous Orphenadrine Objective And Subjective Measurement Of Effect In The Chronic Pain Patient. Pain.(SUPPL. 4):S310, 1987. 198. Nicolucci, A.; Prato S.D., and Vespasiani, G. Optimizing basal-plus insulin therapy in type 2 diabetes (T2D): Impact on patient (Pt) quality of life (QoL) and treatment satisfaction (TS) - The ELEONOR study. Diabetes. Conference: 69th Annual Meeting of the American Diabetes Association New Orleans, LA United States. 199. Nossek, E.; Sitt, R.; Harosh C.B.; Bokstein, F.; Blumenthal D.T.; Korn, B., and Ram, Z. Outcome of an aggressive treatment paradigm of patients with rapid early recurrent GBM. Neuro-Oncology. Conference: 2009 Joint Meeting of the Society for Neuro-Oncology (SNO) and the American Association of Neurological Surgeons/Congress of Neurological Surgeons (AANS/CNS) Section on Tumors New Orleans, LA United States. 200. Offermann, G. Korn A. Safety and tolerability of CyA microemulsion formulation (Sandimmun Neoral) in stable renal transplant patients after 24 months of treatment. German Neoral Study Group. Transplantation. proceedings. 28(4):2204-6, 1996 Aug. 201. Ohning, G. Walsh JH, Thomas D, Decktor D, Korn S, Murakami A, Stauffer L. Famotidine/antacid combination is superior in overall control of gastric acid output compared to ranitidine 75 mg or calcium carbonate 1000 mg. Practical. Gastroenterology. 24(9):37-42, 2000. 202. Olsson, P. G.; Sutherland, H. F.; Nowicka, U.; Korn, B.; Poustka, A., and Frischauf, A. M. The mouse homologue of the tuberin gene (TSC2) maps to a conserved synteny group between mouse chromosome 17 and human 16p13.3. Genomics. 25(1):339- 40, 1995 Jan 1. 203. Paleologo, G.; Tregnaghi, C.; Bianchi A.M.; Barsotti, M.; Nerucci, B.; Marchetti, P.; Coppelli, A.; Giannarelli, R.; Boggi, U.; Vistoli, F.; Prato S.D.; Mosca, F., and Rizzo, G.

WorkSafeBC Evidence-Based Practice Group January 2016 www.worksafebc.com/evidence Treating Mesothelioma: Reviewing Multiple Treatment Modalities 24

Solitary pancreas transplantation: Preliminary findings about early reduction of proteinuria in incipient or evident diabetic type I nephropathy. Transplantation. Proceedings. 36 (3) (pp 591-596), 2004. Date of Publication: April 2004. 204. Patel, S. T. Haser PB, Korn P, Bush HL, Deitch JS, Kent KC. Is carotid endarterectomy cost-effective in symptomatic patients with moderate (50% to 69%) stenosis? Journal. of vascular surgery. 30(6):1024-33, 1999 Dec. 205. Pavord, I. D. Korn S, Howarth P, Bleecker ER, Buhl R, Keene ON, Ortega H, Chanez P. Mepolizumab for severe eosinophilic asthma (DREAM): a multicentre, double-blind, placebo-controlled trial. Lancet. 380(9842):651-9, 2012 Aug. 206. Pavord, I. Korn S, Howarth P, Bleecker E, Buhl R, Keene O, et al. Mepolizumab (anti- IL-5) reduces exacerbations in patients with refractory eosinophilic asthma . European. Respiratory Journal: European Respiratory Society Annual Congress, Vienna, Austria, September 1-5. 40(Suppl 56):36s [349], 2012. 207. Penno, G.; Pucci, L.; Lucchesi, D.; Lencioni, C.; Iorio M.C.; Vanacore, R.; Storti, E.; Resi, V.; Di Cianni, G., and Prato S.D. Circulating endothelial progenitor cells in women with gestational alterations of glucose tolerance. Diabetes. and Vascular Disease Research. 8 (3) (pp 202-210), 2011. Date of Publication: July 2011. 208. Pethig, K. Geiger M, Korn A, Grote M, Christians U, Wahlers T. Follow-up after conversion to Neoral in stable heart transplant recipients. Transplantation. proceedings. 28(4):2282-4, 1996 Aug. 209. Pethig, K. Geiger M, Korn A, Grote M, Christians U, Wahlers T. Conversion from Sandimmune to Neoral in stable heart transplant recipients. Transplantation. proceedings. 28(4):2287-9, 1996 Aug. 210. Postlethwaite, A. E. Wong WK, Clements P, Chatterjee S, Fessler BJ, Kang AH, Korn J, Mayes M, Merkel PA, Molitor JA, Moreland L, Rothfield N, Simms RW, Smith EA, Spiera R, Steen V, Warrington K, White B, Wigley F, Furst DE. A multicenter, randomized, double-blind, placebo-controlled trial of oral type I collagen treatment in patients with diffuse cutaneous systemic sclerosis: I. oral type I collagen does not improve skin in all patients, but may improve skin in late-phase disease. Arthritis. and rheumatism. 58(6):1810-22, 2008 Jun. 211. Poustka, A. ; Dietrich, A. ; Kioschis, P. ; Korn, B. ; Gross, B. ; Monaco, A. ; Toniolo, D. ; Warren, S. , And Lehrach, H. Molecular Characterization Of The Fragile X Region. Cytogenetics. & Cell Genetics. 58(1-4):2082, 1991. 212. Poustka, A. ; Dietrich, A. ; Korn, B. ; Gross, B. ; Monaco, A. ; Toniolo, D. ; Warren, S. , And Lehrach, H. . Molecular Characterisation Of The Fragile X Region. American. Journal of Human Genetics. 49(4 SUPPL):75, 1991. 213. Prato S.D. Type 2 diabetes mellitus: Focus on new treatments and special populations. International. Journal of Clinical Practice. 61 (SUPPL. 154) (pp 1-2), 2007. Date of Publication: August 2007. 214. Prato S.D.; Lasalle, J.; Matthaei, S., and Bailey C.J. Tailoring treatment to the individual in type 2 diabetes practical guidance from the Global Partnership for Effective Diabetes Management. International. Journal of Clinical Practice. 64 (3) (pp 295-304), 2010. Date of Publication: February 2010. 215. Prato, S. D.; LaSalle, J.; Matthaei, S.; Bailey, C. J., and Global Partnership for Effective Diabetes Management. Tailoring treatment to the individual in type 2

WorkSafeBC Evidence-Based Practice Group January 2016 www.worksafebc.com/evidence Treating Mesothelioma: Reviewing Multiple Treatment Modalities 25

diabetes practical guidance from the Global Partnership for Effective Diabetes Management. . International. Journal of Clinical Practice. 64(3):295-304, 2010 Feb. 216. Prato S.D. and Tiengo, A. The importance of first-phase insulin secretion: Implications for the therapy of type 2 diabetes mellitus. Diabetes/Metabolism. Research and Reviews. 17 (3) (pp 164-174), 2001. Date of Publication: 2001. 217. Pucci, L.; Lucchesi, D.; Longo, V.; Prato S.D., and Maffei, S. Lack of association between CYP21 V281L variant and polycystic ovary syndrome in Italian women. Gynecological. Endocrinology. 26 (8) (pp 596-599), 2010. Date of Publication: August 2010. 218. Ratheiser, K. Korn A, Waldhausl W, Komjati M, Vierhapper H, Badian M, Malerczyk V. Dose relationship of stimulated insulin production following intravenous application of glimepiride in healthy man. Arzneimittel-Forschung. 43(8):856-8, 1993 Aug. 219. Ratheiser, K. Korn A, Waldhausl W, Komjati M, Vierhapper H, Badian M, Malerczyk V. Inhibition by etomoxir of carnitine palmitoyltransferase I reduces hepatic glucose production and plasma lipids in non-insulin-dependent diabetes mellitus. METAB. CLIN EXP. 40(11):1185-1190, 1991. 220. Reuter, S.; Bartelmann, M.; Vogt, M.; Geisen, C.; Napierski, I.; Kahn, T.; Delius, H.; Lichter, P.; Weitz, S.; Korn, B., and Schwarz, E. APM-1, a novel human gene, identified by aberrant co-transcription with papillomavirus oncogenes in a cervical carcinoma cell line, encodes a BTB/POZ-zinc finger protein with growth inhibitory activity. EMBO. Journal. 17(1):215-22, 1998 Jan 2. 221. Riedel, A.; End, C.; Christiansen, H.; Renner, M.; Bender, C.; Schmidt, S.; Korn, B.; Sueltmann, H., and Mollenhauer, J. Construction of biosensor systems for determining the pathophysiological potential of carrageenan variants. Molecular. Biosystems. 5(9):973-9, 2009 Sep. 222. Rogers, M. A.; Langbein, L.; Winter, H.; Ehmann, C.; Praetzel, S.; Korn, B., and Schweizer, J. Characterization of a cluster of human high/ultrahigh sulfur keratin- associated protein genes embedded in the type I keratin gene domain on chromosome 17q12-21. Journal. of Biological Chemistry. 276(22):19440-51, 2001 Jun 1. 223. Rogner, U. C.; Heiss, N. S.; Kioschis, P.; Wiemann, S.; Korn, B., and Poustka, A. Transcriptional analysis of the candidate region for incontinentia pigmenti (IP2) in Xq28. Genome. Research. 6(10):922-34, 1996 Oct. 224. Rogner, U. C.; Wilke, K.; Steck, E.; Korn, B., and Poustka, A. The melanoma antigen gene (MAGE) family is clustered in the chromosomal band Xq28. Genomics. 29(3):725-31, 1995 Oct 10. 225. Rolfs, A.; Hu, Y.; Ebert, L.; Hoffmann, D.; Zuo, D.; Ramachandran, N.; Raphael, J.; Kelley, F.; McCarron, S.; Jepson D.A.; Shen, B.; Baqui M.M.A.; Pearlberg, J.; Taycher, E.; DeLoughery, C.; Hoerlein, A.; Korn, B., and LaBaer, J. A biomedically enriched collection of 7000 human ORF clones. PLoS. ONE. 3 (1) , 2008. Article Number: e1528. Date of Publication: 30 Jan 2008. 226. Russo, E.; Pucci, L.; Lucchesi, D.; Dell'omo, G.; Storti, E.; Blanch, C.; Daniele, A.; Penno, G.; Prato S.D.; Pedrinelli, R., and Miccoli, R. Paraoxonase gene polymorphisms are associated with carotid arterial wall thickness in hypertensive subjects with metabolic syndrome. Diabetes. Conference: 69th Annual Meeting of the American Diabetes Association New Orleans, LA United States.

WorkSafeBC Evidence-Based Practice Group January 2016 www.worksafebc.com/evidence Treating Mesothelioma: Reviewing Multiple Treatment Modalities 26

227. Sandoval, N.; Bauer, D.; Brenner, V.; Coy, J. F.; Drescher, B.; Kioschis, P.; Korn, B.; Nyakatura, G.; Poustka, A.; Reichwald, K.; Rosenthal, A., and Platzer, M. The genomic organization of a human creatine transporter (CRTR) gene located in Xq28. Genomics. 35(2):383-5, 1996 Jul 15. 228. Schroth, A; Sipos, B. ; Huber, W. ; Guessow, D. ; Kloeppel, G. ; Kremer, B. ; Hensch, B. ; Grell, M. ; Poustka, A. ; Kalthoff, H. ; Matzku, S. , and Korn, B. . Identification of differentially expressed genes in colon carcinoma by pairwise hybridization of normal and tumor tissue on global human cDNA arrays. European. Journal of Human Genetics. 9(Supplement 1):P0094, 2001. 229. Sedlacek, Z.; Konecki, D. S.; Korn, B.; Klauck, S. M., and Poustka, A. Evolutionary conservation and genomic organization of XAP-4, an Xq28 located gene coding for a human rab GDP-dissociation inhibitor (GDI). Mammalian. Genome. 5(10):633-9, 1994 Oct. 230. Sedlacek, Z.; Korn, B.; Konecki, D. S.; Siebenhaar, R.; Coy, J. F.; Kioschis, P., and Poustka, A. Construction of a transcription map of a 300 kb region around the human G6PD locus by direct cDNA selection. Human. Molecular Genetics. 2(11):1865-9, 1993 Nov. 231. Seibold, J. R. Korn JH, Simms R, Clements PJ, Moreland LW, Mayes MD, Furst DE, Rothfield N, Steen V, Weisman M, Collier D, Wigley FM, Merkel PA, Csuka ME, Hsu V, Rocco S, Erikson M, Hannigan J, Harkonen WS, Sanders ME. Recombinant human relaxin in the treatment of scleroderma. A randomized, double-blind, placebo- controlled trial. Annals. of internal medicine. 132(11):871-9, 2000 Jun. 232. Seranski, P.; Heiss, N. S.; Dhorne-Pollet, S.; Radelof, U.; Korn, B.; Hennig, S.; Backes, E.; Schmidt, S.; Wiemann, S.; Schwarz, C. E.; Lehrach, H., and Poustka, A. Transcription mapping in a medulloblastoma breakpoint interval and Smith-Magenis syndrome candidate region: identification of 53 transcriptional units and new candidate genes. Genomics. 56(1):1-11, 1999 Feb 15. 233. Seranski, P. ; Pollet, S. ; Korn, B. ; Wiemann, S. ; Heiss, N. , and Poustka, A. . Transcript mapping and genomic characterization in an unstable interval on chromosome 17p11.2. American. Journal of Human Genetics. 61(4 SUPPL.):A81, Oct., 1997. 234. Seranski, P. ; Radelof, U. ; Heiss, N. ; Wiemann, D. ; Korn, B. ; Backes, E. ; Scheurlen, W. ; Strand, D. ; Lehrach, H. , and Poustka, A. . Molecular analysis of the human chromosome 17p11.2: From breakpoint identification to sequencing and gene analysis. Journal. of Molecular Medicine (Berlin). 76(6):B38, May, 1998. 235. Shank M.L.; Prato S.D., and DeFronzo R.A. Bedtime insulin/daytime glipizide: Effective therapy for sulfonylurea failures in NIDDM. Diabetes. 44 (2) (pp 165-172), 1995. Date of Publication: 1995. 236. Sharma, N. C. Galustians J, Rustogi KN, McCool JJ, Petrone M, Volpe AR, Korn LR, Petrone D. Comparative plaque removal efficacy of three toothbrushes in two independent clinical studies. The. Journal of clinical dentistry. 3(Suppl C):C13-20, 1992. 237. Singh, S. M. Rustogi KN, McCool JJ, Petrone M, Volpe AR, Korn LR, Petrone D. Clinical studies regarding the plaque removal efficacy of manual toothbrushes. The. Journal of clinical dentistry. 3(Suppl C):C21-28, 1992.

WorkSafeBC Evidence-Based Practice Group January 2016 www.worksafebc.com/evidence Treating Mesothelioma: Reviewing Multiple Treatment Modalities 27

238. Sperschneider, H. Wagner C, Korn A, Christian U. Effect of diltiazem on cyclosporine metabolites through blood concentrations after Sandimmun (R) and Neoral (R) in renal transplant patients. DER EINFLUSS VON DILTIAZEM AUF DIE KONZENTRATION VON CYCLOSPORIN-METABOLITEN BEI MIT SANDIMMUN UND NEORAL BEHANDELTEN NIERENTRANSPLANTIERTEN PATIENTEN. Medizinische. Klinik. 92(10):589-596, 1997. 239. Sperschneider, H. Wagner C, Korn A, Christian U. [Effect of diltiazem on concentration of cyclosporin metabolites in Sandimmune and Neoral treated kidney transplant patients]. Medizinische. Klinik (Munich, Germany :. 1983) 92(10):589-96, 1997 Oct. 240. Steinsson, K. Weinstein A, Korn J, Abeles M. Low dose methotrexate in rheumatoid arthritis. The. Journal of rheumatology. 9(6):860-6, 1982 Nov-Dec. 241. Stelzl, U.; Worm, U.; Lalowski, M.; Haenig, C.; Brembeck, F. H.; Goehler, H.; Stroedicke, M.; Zenkner, M.; Schoenherr, A.; Koeppen, S.; Timm, J.; Mintzlaff, S.; Abraham, C.; Bock, N.; Kietzmann, S.; Goedde, A.; Toksoz, E.; Droege, A.; Krobitsch, S.; Korn, B.; Birchmeier, W.; Lehrach, H., and Wanker, E. E. A human protein-protein interaction network: a resource for annotating the proteome. Cell. 122(6):957-68, 2005 Sep 23. 242. Stibbs, G. D. and Korn JH. An evaluation of the local anaesthetic mepivacaine hydrochloride in operative dentistry. Journal. of Prosthetic Dentistry. 14(2):1964. 243. Storti, E.; Pucci, L.; Lucchesi, D.; Vanacore, R.; Iorio, M.; Ghiadoni, L.; Russo, E.; Bianchi, C.; Daniele, A.; Taddei, S.; Miccoli, R.; Penno, G., and Prato S.D. Inflammation, oxidative stress and Endothelial function in subjects with normal, impaired, and diabetic glucose tolerance. Diabetes. Conference: 69th Annual Meeting of the American Diabetes Association New Orleans, LA United States. 244. Taussig M.J.; Stoevesandt, O.; Borrebaeck C.A.K.; Bradbury A.R.; Cahill, D.; Cambillau, C.; de Daruvar, A.; Dubel, S.; Eichler, J.; Frank, R.; Gibson T.J.; Gloriam, D.; Gold, L.; Herberg F.W.; Hermjakob, H.; Hoheisel J.D.; Joos T.O.; Kallioniemi, O.; Koegl, M.; Konthur, Z.; Korn, B.; Kremmer, E.; Krobitsch, S.; Landegren, U.; van der Maarel, S.; McCafferty, J.; Muyldermans, S.; Nygren P.-A.; Palcy, S.; Pluckthun, A.; Polic, B.; Przybylski, M.; Saviranta, P.; Sawyer, A.; Sherman D.J.; Skerra, A.; Templin, M.; Ueffing, M., and Uhlen, M. Erratum: Detection of minor drug-resistant populations by parallel allele-specific sequencing (Nature Methods). Nature. Methods. 4 (2) (pp 187), 2007. Date of Publication: February 2007. 245. Taussig M.J.; Stoevesandt, O.; Borrebaeck C.A.K.; Bradbury A.R.; Cahill, D.; Cambillau, C.; de Daruvar, A.; Dubel, S.; Eichler, J.; Frank, R.; Gibson T.J.; Gloriam, D.; Gold, L.; Herberg F.W.; Hermjakob, H.; Hoheisel J.D.; Joos T.O.; Kallioniemi, O.; Koegll, M.; Konthur, Z.; Korn, B.; Kremmer, E.; Krobitsch, S.; Landegren, U.; van der Maarel, S.; McCafferty, J.; Muyldermans, S.; Nygren P.-A.; Palcy, S.; Pluckthun, A.; Polic, B.; Przybylski, M.; Saviranta, P.; Sawyer, A.; Sherman D.J.; Skerra, A.; Templin, M.; Ueffing, M., and Uhlen, M. ProteomeBinders: Planning a European resource of affinity reagents for analysis of the human proteome. Nature. Methods. 4 (1) (pp 13-17), 2007. Date of Publication: January 2007. 246. Teufel, A.; Becker, D.; Weber, S. N.; Dooley, S.; Breitkopf-Heinlein, K.; Maass, T.; Hochrath, K.; Krupp, M.; Marquardt, J. U.; Kolb, M.; Korn, B.; Niehrs, C.; Zimmermann, T.; Godoy, P.; Galle, P. R., and Lammert, F. Identification of RARRES1

WorkSafeBC Evidence-Based Practice Group January 2016 www.worksafebc.com/evidence Treating Mesothelioma: Reviewing Multiple Treatment Modalities 28

as a core regulator in liver fibrosis. Journal. of Molecular Medicine. 90(12):1439-47, 2012 Dec. 247. Teyssen, S. Lenzing T, Gonzalez-Calero G, Korn A, Riepl RL, Singer MV. Alcoholic beverages produced by alcoholic fermentation but not by distillation are powerful stimulants of gastric acid secretion in humans. Gut. 40(1):49-56, 1997 Jan. 248. Torri, V. Korn EL, Simon R. Dose intensity analysis in advanced ovarian cancer patients. British. Journal of Cancer. Vol.67, pp.190-7, 1993. 249. Trevisan, R.; Bruttomesso, D.; Vedovato, M.; Brocco, S.; Pianta, A.; Mazzon, C.; Girardi, C.; Jori, E.; Semplicini, A.; Tiengo, A., and Prato S.D. Enhanced responsiveness of blood pressure to sodium intake and to angiotensin II is associated with insulin resistance in IDDM patients with microalbuminuria. Diabetes. 47 (8) (pp 1347-1353), 1998. Date of Publication: 1998. 250. Tutuian, R. Katz PO, Ahmed F, Korn S, Castell DO. Over-the-counter H(2)-receptor antagonists do not compromise intragastric pH control with proton pump inhibitors. Alimentary. pharmacology & therapeutics. 16(3):473-7, 2002 Mar. 251. van der Kolk, B. A. Spinazzola J, Blaustein ME, Hopper JW, Hopper EK, Korn DL, Simpson WB. A randomized clinical trial of eye movement desensitization and reprocessing (EMDR), fluoxetine, and pill placebo in the treatment of posttraumatic stress disorder: treatment effects and long-term maintenance. The. Journal of clinical psychiatry. 68(1):37-46, 2007 Jan. 252. Vanhoefer, U. Wilke H, Fink U, Kohne Wompner C, Preusser P, Korn WM, Stahl M, Achterrath W, Harstrick A, Klaassen U. Weekly 24-hr infusion of high-dose FU (HD- FU) plus folinic acid (FA) plus biweekly cisplatin (C) = (group A) or HD-FU/FA/C plus epirubicin (E) = (group B) in locally advanced (LAD) or metastatic (M1) advanced gastric cancer (GC) . Proc-Annu-Meet-Am-Soc-Clin-Oncol. Vol.14, pp.ABS. A464, 1995. 253. Vente, A.; Korn, B.; Zehetner, G.; Poustka, A., and Lehrach, H. Distribution and early development of microarray technology in Europe [6]. Nature. Genetics. 22 (1) (pp 22), 1999. Date of Publication: 1999. 254. Vente, A. ; Kioschis, P. ; Korn, B. ; Maurer, C. ; Zehetner, G. ; Poustka, A. , and Lehrach, H. . Resource Center / Primary Database of the German Human Genome Project. American. Journal of Human Genetics. 65(4):A422, Oct., 1999. 255. Verho, M. Korn A, Badian M, Malerczyk V, Waldhausl W. Dose linearity testing of intravenous ofloxacin, a novel gyrase inhibitor. Chemotherapy. 34(3):170-177, 1988. 256. Verho, M. Korn A, Badian M, Malerczyk V, Waldhausl W. Dose linearity and other pharmacokinetics of ofloxacin: a new, broad-spectrum antimicrobial agent. Pharmatherapeutica. 4(6):376-82, 1985. 257. Verho, M. Korn A, Badian M, Malerczyk V, Waldhausl W. The effect of food on the pharmacokinetics of ofloxacin. Current. medical research and opinion. 10(3):166-71, 1986. 258. Vierhapper, H. Grubeck-Loebenstein B, Korn A, Waldhausl W. Effect of inhibition of prostaglandin: synthesis upon the vasoactive effects of endogenous and exogenous cetecholamines . European. Journal of Clinical Investigation. Vol.10 (2 Pt II), pp.39, 1980. 259. Vits, L.; Van Camp, G.; Coucke, P.; Fransen, E.; De Boulle, K.; Reyniers, E.; Korn, B.; Poustka, A.; Wilson, G.; Schrander-Stumpel, C.; Winter R.M.; Schwartz, C., and

WorkSafeBC Evidence-Based Practice Group January 2016 www.worksafebc.com/evidence Treating Mesothelioma: Reviewing Multiple Treatment Modalities 29

Willems P.J. MASA syndrome is due to mutations in the neural cell adhesion gene L1CAM. Nature. Genetics. 7 (3) (pp 408-413), 1994. Date of Publication: July 1994. 260. Volpe, L.; Cuccuru, I.; Lencioni, C.; Napoli, V.; Ghio, A.; Fotino, C.; Bertolotto, A.; Penno, G.; Benzi, L.; Prato S.D., and Cianni G.D. Early Subclinical Atherosclerosis in Women with Previous Gestational Diabetes Mellitus. Diabetes. Care. 31 (5) (pp E32), 2008. Date of Publication: May 2008. 261. Wagner, C. Sperschneider H, Korn A, Christians U. Influence of diltiazem on cyclosporine metabolites in renal graft recipients treated with Sandimmun and Neoral . Journal. of the American Society of Nephrology. 8(Program & Abstracts):707a, 1997. 262. Wagner, K.; Mincheva, A.; Korn, B.; Lichter, P., and Popperl, H. Pbx4, a new Pbx family member on mouse chromosome 8, is expressed during spermatogenesis. Mechanisms. of Development. 103(1-2):127-31, 2001 May. 263. Wagner, W.; Bork, S.; Pfister, S.; Horn, P.; Witt, H.; Korn, B., and Ho, A. DNA methylation is regulated upon long-term culture and aging of human mesenchymal stromal cells. Human. Gene Therapy. Conference: Combined Meeting 2009 - 17th Annual Congress of the European Society of Gene and Cell Therapy, ESGCT, 4th Annual Congress of the German Society for Stem Cell Research, GSZ, 16th Annual Meeting of the German Society for Gene Therapy, DG-GT, Co-organized by the European Branch of the International Society for Cellular Therapy, ISCT Hannover Germany. 264. Waldeck, W.; Pipkorn, R.; Korn, B.; Mueller, G.; Schick, M.; Toth, K.; Wiessler, M.; Didinger, B., and Braun, K. Transporter molecules influence the gene expression in HeLa cells. International. Journal of Medical Sciences. 6(1):18-27, 2009. 265. Wetzler, S. Kahn RS, Asnis GM, Korn M, van Praag HM. Serotonin receptor sensitivity and aggression. Psychiatry. research. 37(3):271-9, 1991 Jun. 266. White, P.; Korn, B.; O'Donnell, R.; Lynch, M.; Corcoran, C.; O'Siorain, L.; Kealy, K., and Latham, J. Improving palliative care for respiratory patients-piloting the role of a novel multidisciplinary team meeting. Irish. Journal of Medical Science. Conference: Irish Thoracic Society Annual Scientific Meeting 2011 Co. Dublin Ireland. 267. White, P.; Korn, B.; O'Donnell, R.; Lynch, M.; Edghill, A.; Corcoran, C.; O'Siorain, L.; Kealy, K., and Latham, J. Improving palliative care for respiratory patients-an analysis of the palliative care educational needs of respiratory staff. Irish. Journal of Medical Science. Conference: Irish Thoracic Society Annual Scientific Meeting 2011 Co. Dublin Ireland. 268. Wiemann, S.; Weil, B.; Wellenreuther, R.; Gassenhuber, J.; Glassl, S.; Ansorge, W.; Bocher, M.; Blocker, H.; Bauersachs, S.; Blum, H.; Lauber, J.; Dusterhoft, A.; Beyer, A.; Kohrer, K.; Strack, N.; Mewes, H. W.; Ottenwalder, B.; Obermaier, B.; Tampe, J.; Heubner, D.; Wambutt, R.; Korn, B.; Klein, M., and Poustka, A. Toward a catalog of human genes and proteins: sequencing and analysis of 500 novel complete protein coding human cDNAs. Genome. Research. 11(3):422-35, 2001 Mar. 269. Wiench, B.; Eichhorn, T.; Korn, B.; Paulsen, M., and Efferth, T. Utilizing inherent fluorescence of therapeutics to analyze real-time uptake and multi-parametric effector kinetics. Methods. (Duluth). 57(3):376-82, 2012 Jul. 270. Wigley, F. M. Korn JH, Csuka ME, Medsger TA, Rothfield NF, Ellman M, Martin R, Collier DH, Weinstein A, Furst DE, Jimenez SA, Mayes MD, Merkel PA, Gruber B,

WorkSafeBC Evidence-Based Practice Group January 2016 www.worksafebc.com/evidence Treating Mesothelioma: Reviewing Multiple Treatment Modalities 30

Kaufman L, Varga J, Bell P, Kern J, Marrott P, White B, Simms RW, Phillips AC, Seibold JR. Oral iloprost treatment in patients with Raynaud's phenomenon secondary to systemic sclerosis: a multicenter, placebo-controlled, double-blind study. Arthritis. and rheumatism. 41(4):670-7, 1998 Apr. 271. Wilgenbus K.K.; Mincheva, A.; Korn, B.; Lichter, P., and Poustka, A. IRS-long range (LR) PCR: A simple method for efficient amplification of human genomic DNA from complex sources. Methods. in Molecular and Cellular Biology. 5 (4) (pp 214-221), 1995. Date of Publication: 1994. 272. Wilke, H. Korn M, Vanhofer U, Fink U, Stahl M, Preusser P, Kohne C, Klassen U, Harstrick A, Schmoll HJ, Seeber S. Weekly infusional 5-fluorouracil plus/minus other drugs for the treatment of advanced gastric cancer. The. Journal of infusional chemotherapy. 6(3):123-6, 1996. 273. Will, R. D.; Eden, M.; Just, S.; Hansen, A.; Eder, A.; Frank, D.; Kuhn, C.; Seeger, T. S.; Oehl, U.; Wiemann, S.; Korn, B.; Koegl, M.; Rottbauer, W.; Eschenhagen, T.; Katus, H. A., and Frey, N. Myomasp/LRRC39, a heart- and muscle-specific protein, is a novel component of the sarcomeric M-band and is involved in stretch sensing. Circulation. Research. 107(10):1253-64, 2010 Nov 12. 274. Will R.D.; Just, S.; Spaich, S.; Kuhn, C.; Frank, D.; Berger I.M.; Wiemann, S.; Korn, B.; Koegl, M.; Backs, J.; Katus H.A.; Rottbauer, W., and Frey, N. F-box and leucine- rich repeat protein 22 is a cardiac-enriched f-box protein that regulates sarcomeric protein turnover and is essential for maintenance of contractile function in vivo. Circulation. Research. 111 (12) (pp 1504-1516), 2012. Date of Publication: December 2012. 275. Winchell, G. A. King JD, Chavez-Eng CM, Constanzer ML, Korn SH. Cyclobenzaprine pharmacokinetics, including the effects of age, gender, and hepatic insufficiency. Journal. of clinical pharmacology. 42(1):61-9, 2002 Jan. 276. Wirkner, U. ; Maercker, C. ; Wagner, M. ; Selig, J. ; Drzonek, H. ; Radelof, U. ; Kellermann, A. ; Ansorge, A. ; Paces, O. ; Maurer, J. ; Schwager, C. ; Korn, B. , and Ansorge, W. . Human genome on a chip for stem cell research. Molecular. & Cellular Proteomics. 2(9):925, September 2003. 277. Wittig, R.; Nessling, M.; Will, R. D.; Mollenhauer, J.; Salowsky, R.; Munstermann, E.; Schick, M.; Helmbach, H.; Gschwendt, B.; Korn, B.; Kioschis, P.; Lichter, P.; Schadendorf, D., and Poustka, A. Candidate genes for cross-resistance against DNA- damaging drugs. Cancer. Research. 62(22):6698-705, 2002 Nov 15. 278. Wittig, R. ; Nessling, M. ; Korn, B. ; Lichter, P. ; Schadendorf, D. , and Poustka, A. . Characterization of drug resistant malignant melanoma cells by gene expression profiling. American. Journal of Human Genetics. 69(4 Supplement):273, October, 2001. 279. Wohrle, D.; Kotzot, D.; Hirst, M. C.; Manca, A.; Korn, B.; Schmidt, A.; Barbi, G.; Rott, H. D.; Poustka, A.; Davies, K. E. and others. A microdeletion of less than 250 kb, including the proximal part of the FMR-I gene and the fragile-X site, in a male with the clinical phenotype of fragile-X syndrome. American. Journal of Human Genetics. 51(2):299-306, 1992 Aug. 280. Xu, T. M. Zhang X, Oh HS, Boyd RL, Korn EL, Baumrind S. Randomized clinical trial comparing control of maxillary anchorage with 2 retraction techniques. American. journal of orthodontics and dentofacial orthopedics : official publication of the

WorkSafeBC Evidence-Based Practice Group January 2016 www.worksafebc.com/evidence Treating Mesothelioma: Reviewing Multiple Treatment Modalities 31

American Association of Orthodontists, its constituent societies, and the American Board of Orthodontics. 138(5):544.e1-9; discussion 544-5, 2010 Nov. 281. Yaspo, M. L.; Gellen, L.; Mott, R.; Korn, B.; Nizetic, D.; Poustka, A. M., and Lehrach, H. Model for a transcript map of human chromosome 21: isolation of new coding sequences from exon and enriched cDNA libraries. Human. Molecular Genetics. 4(8):1291-304, 1995 Aug. 282. Yaspo, M. L. ; Szulzedsky, I. ; Hunt, E. ; Nguyen, M. ; Korn, B. ; Kong, X. ; O'Brian, J. , and Lehrach, H. . The chromosome 21 transcript map: How far from completion with more than 3,000 ESTs: Impact for the molecular genetics of Down syndrome. Cytogenetics. & Cell Genetics. 77(SUPPL. 1):13-14, 1997. 283. Yaspo, M.-L. ; Szulzedsky, I. ; Haaf, T. ; Korn, B. ; Burgtorf, C. ; Poustka, A. , and Lehrach, H. . Progress in constructing a transcript map for Chr21: Analysis and distribution of genes isolated from 20 Mb of random DNA. Cytogenetics. & Cell Genetics. 79(1-2):45, 1997. 284. Yuille, M.; Korn, B.; Moore, T.; Farmer A.A.; Carrino, J.; Prange, C., and Hayashizaki, Y. The responsibility to share: Sharing the responsibility. Genome. Research. 14 (10 B) (pp 2015-2019), 2004. Date of Publication: October 2004. 285. Zimmer, R. Puech AJ, Philipp F, Korn A. Interaction between orally administered tyramine and moclobemide. Acta. Psychiatrica Scandinavica, Supplement. 82(360):78-80, 1990. 286. Zink, D. ; Haas, S. ; Coward, E. ; Vingron, M. , and Korn, B. . Experimental verification of predicted splice variants of human genes. European. Journal of Human Genetics. 10(Supplement 1):166, 2002. 287. Attisano, C.; Bianchi, A.; Montacchini, L.; Carlesso, N.; Peola, S.; Bruno, B.; Roux, V.; Ferrero, D.; Gallo, E.; Boccadoro, M. and others. Generation of anti-tumour activity by OKT3-stimulation in multiple myeloma: in vitro inhibition of autologous haemopoiesis. British. Journal of Haematology. 87(3):494-502, 1994 Jul. 288. Baron, F. and Storb, R. The immune system as a foundation for immunologic therapy and hematologic malignancies: a historical perspective. Best. Practice and Research: Clinical Haematology. 19 (4) (pp 637-653), 2006. Date of Publication: December 2006. 289. Centre for Reviews and Dissemination. CD40-activated human B cells: an alternative source of highly efficient antigen presenting cells to generate autologous antigen- specific T cells for adoptive immunotherapy (Structured abstract). NHS. Economic Evaluation Database (NHSEED). Critically appraised economic evaluations. 2013 Issue 3, John Wiley & Sons, Ltd. Chichester, UK. Division: ST. 290. Dahmani, A.; Carli, C.; Caron L.-P.; Jean, C.; Giroux, M., and Delisle J.-S. The immune "combination therapy" of leukemia using adoptive transfer and TGF-beta blockade. Blood. Conference: 54th Annual Meeting of the American Society of Hematology, ASH 2012 Atlanta, GA United States. 291. Gao, Y.; Wei, L.; Chen H.S.; Sun, J.; Wang S.X., and Wang, Y. Autologous adoptive immunotherapy without destruction of infected cells during the treatment of chronic hepatitis B. Zhonghua. gan zang bing za zhi = Zhonghua ganzangbing zazhi = Chinese journal of hepatology. 11 (7) (pp 391-393), 2003. Date of Publication: Jul 2003.

WorkSafeBC Evidence-Based Practice Group January 2016 www.worksafebc.com/evidence Treating Mesothelioma: Reviewing Multiple Treatment Modalities 32

292. Kim, E.; Ahn Y.-O.; Kim, S.; Kim T.M.; Keam, B., and Heo D.S. Ex vivo activation and expansion of natural killer cells from advanced cancer patients with feeder cells from healthy volunteers. Cancer. Research. Conference: 103rd Annual Meeting of the American Association for Cancer Research, AACR 2012 Chicago, IL United States. 293. Sangiolo, D.; Mesiano, G.; Todorovic, M.; Cammarata, C.; Muraro, M.; Mereuta, M.; Saglio, F.; Caione, L.; Grignani, G.; Carnevale-Schianca, F.; Cignetti, A.; Fagioli, F., and Aglietta, M. Potent in vitro tumour killing of patients' cytokine-induced killer cells against metastatic osteosarcoma. Bone. Marrow Transplantation. Conference: 36th Annual Meeting of the European Group for Blood and Marrow Transplantation, EBMT 2010 Vienna Austria. 294. Schultze J.L.; Michalak, S.; Seamon M.J.; Dranoff, G.; Jung, K.; Daley, J.; Delgado J.C.; Gribben J.G., and Nadler L.M. CD40-activated human B cells: An alternative source of highly efficient antigen presenting cells to generate autologous antigen- specific T cells for adoptive immunotherapy. Journal. of Clinical Investigation. 100 (11) (pp 2757-2765), 1997. Date of Publication: 01 Dec 1997. 295. Sherif A.M.; Eriksson, E.; Thorn, M.; Vasko, J.; Ohberg, L.; Riklund, K., and Ljungberg, B. Sentinel node detection in renal cell carcinoma. A feasibility study. European. Urology, Supplements. Conference: 27th Annual Congress of the European Association of Urology, EAU Paris France. 296. Van Lunzen, J.; Schmitz, J.; Dengler, E.; Schmitz, H., and Dietrich, M.. High yields of CD4+ and CD8+ T-lymphocytes can be obtained by lymphapheresis and ex vivo propagation for autologous adoptive immunotherapy of HIV-infection. AIDS. (Philadelphia). 8(SUPPL. 4):S29, 1994. 297. Yoshizumi, Y. Establishment of cytotoxic lymphocytes against autologous cholangiocarcinoma from the patient's blood lymphocytes cultured in T cell growth factor (TCGF). Nippon. Geka Gakkai zasshi. 85 (6) (pp 563-572), 1984. Date of Publication: Jun 1984. 298. Aliev, D. A And Mamedov, M. K. Some Oncological Aspects Of Hiv Infection. Voprosy. Onkologii (St. Petersburg). 36(5):515-522, 1990. 299. Capobianco, A.; Manfredi A.A.; Monno, A.; Rovere-Querini, P., and Rugarli, C. Melanoma and lymphoma rejection associated with eosinophil infiltration upon intratumoral injection of dendritic and NK/LAK cells. Journal. of Immunotherapy. 31 (5) (pp 458-465), 2008. Date of Publication: June 2008. 300. Motohashi, S.; Okamoto, Y.; Yoshino, I., and Nakayama, T. Anti-tumor immune responses induced by iNKT cell-based immunotherapy for lung cancer and head and neck cancer. Clinical. Immunology. 140 (2) (pp 167-176), 2011. Date of Publication: August 2011. 301. Asjo, B. and Wahren, J. Risk of nosocomial AIDS-virus infection during intravenous nutrition therapy in AIDS patients virus characteristics and precautions. Nutrition. International. 2 (4) (pp 268-270), 1986. Date of Publication: 1986. 302. Bier, I. D. Peripheral intravenous nutrition therapy: outpatient, office-based administration. Alternative. Medicine Review. 5(4):347-54, 2000 Aug. 303. GUSS, W. J and AMENT, M. E. OERSKOVIA INFECTION CAUSED BY CONTAMINATED HOME PARENTERAL NUTRITION SOLUTION. Archives. of Internal Medicine. 149(6):1457-1458, 1989.

WorkSafeBC Evidence-Based Practice Group January 2016 www.worksafebc.com/evidence Treating Mesothelioma: Reviewing Multiple Treatment Modalities 33

304. Holliday M.A.; Wassner, S., and Ramirez, J. Intravenous nutrition in uremic children with protein-energy malnutrition. American. Journal of Clinical Nutrition. 31 (10) (pp 1854-1860), 1978. Date of Publication: 1978. 305. Lawrence, J.; Turner, M., And Gilbert, P. Microbial Contamination And Growth In Total Parenteral Nutrition Solutions. Journal. of Clinical Pharmacy & Therapeutics. 13(2):151-158, 1988. 306. Qiu, H. Q. [The effect of short term intravenous nutrition therapy on the effectiveness of the treatment of pulmonary heart disease with heart-lung failure]. Chinese. Journal of Enteral and Parenteral Nutrition. 6(1):16-19, 1998. 307. Shenkin, A. and Wretlind, A. General aspects concerning the intravenous feeding of cancer patients. Infusionstherapie. und klinische Ernahrung. 5 (3) (pp 156-165), 1978. Date of Publication: Jun 1978. 308. Shenkin, A. and Wretlind, A. General aspects of intravenous feeding of cancer patients. Onkologie. 1 (4) (pp 153-162), 1978. Date of Publication: Aug 1978. 309. Wassner, S. J. Sanders R, Orloff S, Sheldon GF, Holliday MA. A comparison of essential and general amino acid infusions in protein-depleted patients receiving parenteral alimentation. The. American journal of clinical nutrition. 32(7):1497-504, 1979 Jul. 310. Berghmans T, Paesmans M, Lalami Y et al. Activity of chemotherapy and immunotherapy on malignant mesothelioma: a systematic review of the literature with meta analysis. Lung Cancer. 2002;38(2):111-121. 311. Organising Committee. Guidelines for the diagnosis and treatment of malignant pleural mesothelioma. Asbestos Diseases Research Institute. Sydney, NSW, Australia: 2013. available from www.adri.org.au 312. Organising Committee. Guidelines for the diagnosis and treatment of malignant pleural mesothelioma. Technical Report. Asbestos Diseases Research Institute. Sydney, NSW, Australia: 2013. available from http://www.adri.org.au/documents/Technical_Report_Guidelines_diagnosis_and_treat ment_of_malignant_pleural_mesothelioma.pdf 313. Organising Committee. Guidelines for the diagnosis and treatment of malignant pleural mesothelioma. Administrative Report. Asbestos Diseases Research Institute. Sydney, NSW, Australia: 2013. available from http://www.adri.org.au/documents/Administrative_Report_Guidelines_for_the_diagno sis_and_treatment_of_malignant_pleural_mesothelioma.pdf

WorkSafeBC Evidence-Based Practice Group January 2016 www.worksafebc.com/evidence Treating Mesothelioma: Reviewing Multiple Treatment Modalities 34

Appendix 1

WorkSafeBC - Evidence-Based Practice Group Levels of Evidence (adapted from 1,2,3,4) Evidence from at least 1 properly randomized controlled trial 1 (RCT) or systematic review of RCTs. Evidence from well-designed controlled trials without 2 randomization or systematic reviews of observational studies. Evidence from well-designed cohort or case-control analytic 3 studies, preferably from more than 1 centre or research group. Evidence from comparisons between times or places with or 4 without the intervention. Dramatic results in uncontrolled

Opinions of respected authorities, based on clinical experience, 5 descriptive studies or reports of expert committees.

References

1. Canadian Task Force on the Periodic Health Examination: The periodic health examination. CMAJ. 1979;121:1193-1254.

2. Houston TP, Elster AB, Davis RM et al. The US Preventive Services Task Force Guide to Clinical Preventive Services, Second Edition. AMA Council on Scientific Affairs. American Journal of Preventive Medicine. May 1998;14(4):374-376.

3. Scottish Intercollegiate Guidelines Network (2001). SIGN 50: a guideline developers' handbook. SIGN. Edinburgh.

4. Canadian Task Force on Preventive Health Care. New grades for recommendations from the Canadian Task Force on Preventive Health Care. CMAJ. Aug 5, 2003;169(3):207- 208.

WorkSafeBC Evidence-Based Practice Group January 2016 www.worksafebc.com/evidence